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ABSTRACT 
 Polyglutamine diseases refer to a group of neurodegenerative diseases, including 
Huntingtons disease (HD), that share the same mutational basis: expansion of a CAG 
repeat coding sequence that encodes for a polyglutamine repeat in the respective proteins. 
Neuronal intranuclear inclusions (NII) formed by the aggregation of the expanded 
polyglutamine proteins is a hallmark of polyglutamine diseases.  However, it is still under 
debate whether the polyglutamine aggregates are toxic to the cells, and if so, which 
aggregated forms are the toxic species. While important data has been provided by the 
existing transfected cell and transgenic animal models, technical aspects have limited our 
ability to rigorously interpret this data in terms of molecular and cellular mechanism. A 
number of comprehensive studies on in vitro polyglutamine aggregation kinetics, and 
features of the aggregates produced in vitro, provided the foundation to directly address 
the question of the cytotoxicity of polyglutamine aggregates. In the present study, we 
designed a new cell model by directly introducing in vitro synthesized polyglutamine 
aggregates into mammalian cells, both PC-12 and Cos-7, to study the cytotoxicity of 
different forms of aggregates. We found that cell viability was largely unaffected when 
polyglutamine aggregates are localized to the cytoplasm; aggregates of polyglutamine 
peptides containing a nuclear localization signal, however, are localized to nuclei and 
lead to dramatic cell death.  This cytotoxicity is polyglutamine-sequence-specific. We 
also found that a short polyglutamine peptide (Q20), once aggregated and delivered to the 
cell nucleus, seems to be equally cytotoxic. Further studies suggest that the mechanism of 
cell death in this novel model system seems to be apoptotic. Our results support a direct 
vi 
role for polyglutamine aggregates in cytotoxicity and are consistent with a recruitment-
sequestration disease mechanism. This is further supported by studies, also described 
here, in which a polyglutamine aggregation elongation inhibitor protects against cell 
death induced by nuclear polyglutamine aggregates. 
vii 
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CHAPTER 1 
LITERATURE REVIEW 
 
Polyglutamine diseases 
Introduction 
Polyglutamine diseases are a group of neurodegenerative disorders caused by the 
expansion of CAG repeats encoding for polyglutamine tracts in different affected 
proteins (Bates 2002). Since the discovery in 1991 of the expanded CAG repeat mutation 
in the androgen receptor gene (La Spada, Wilson et al. 1991), which is responsible for 
Spinal and Bulbar Muscular Atrophy (SBMA), a total of nine polyglutamine diseases 
have been discovered (Zoghbi and Orr 2000; Bates 2002). These include Huntingtons 
Disease (HD) (Myers, MacDonald et al. 1993), Spinal and Bulbar Muscular Atrophy 
(SBMA) (La Spada, Wilson et al. 1991), Dentatorubral  Pallidoluysian Atrophy 
(DRPLA) (Koide, Ikeuchi et al. 1994; Nagafuchi, Yanagisawa et al. 1994) and several 
forms of Spinocerebellar Ataxia (SCA 1, 2, 3, 6, 7, 17) (Orr, Chung et al. 1993; 
Kawaguchi, Okamoto et al. 1994; Sanpei, Takano et al. 1996; David, Abbas et al. 1997; 
Zhuchenko, Bailey et al. 1997; Koide, Kobayashi et al. 1999). The discoveries of 9 
polyglutamine diseases and the citations of the literatures are summarized in Table 1. 
In the literature, polyglutamine disease is often called expanded CAG repeat 
diseases or disorders (Burright, Orr et al. 1997), (a) because most of polyglutamine  
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Table 1. History of the discovery and research on the 9 polyglutamine diseases 
Diseases 
(abbreviation) 
Year of 
gene 
discovered
Reference on the 
first discovery of 
the gene mutation 
Number of the research papers 
since the discovery (from 
PubMed by Feb. 3, 2003) 
HD 1993 Huntingtons 
Disease 
Collaborative 
Research 
Group1993 
1773 
SBMA 1991 La Spada et al. 
1991 
206 
DRPLA 1994 Koide et al and 
Nagafuchi et al. 
1994 
93 
SCA1 1993 Orr et al, 1993 81 
SCA2 1996 Sanpei et al. 1996 50 
SCA3 1994 Kawaguchi et al. 
1994 
33 
SCA6 1997 Zhuchenko et al. 
1997 
34 
SCA7 1997 David et al. 1997 26 
SCA17 1999 Koide et al. 1999 3 
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sequences in the mutant proteins are coded by a simple, unbroken CAG repeat DNA 
sequence (Bates 2002) (except for in SCA2 and SCA17, in which repeats were 
interrupted with 1-2 CAA, which also codes for glutamine (Costanzi-Porrini, Tessarolo et 
al. 2000; Fujigasaki, Martin et al. 2001)); and (b) because a genetic expansion of this 
sequence from a normal, benign length to a pathogenic length is associated with disease 
(Bates 2002). 
From genetic aspects, polyglutamine diseases belong to a large group of 
hereditary diseases called trinucleotide repeat diseases. To date, there are more than 15 
neurological disorders discovered in this group, including the polyglutamine diseases 
(Cummings and Zoghbi 2000). Expansion of a trinucleotide repeat can occur in any part 
of a gene, in-frame or not. In the nine polyglutamine diseases, however, the expanded 
trinucleotide repeat always lies in-frame in the coding region of a gene, which results in 
normal transcription and translation of the genes to yield a protein with an expanded 
polyglutamine sequence. At the cellular and molecular level, most of the evidence so far 
suggests that these diseases are caused by a toxic gain of function due to the expansion of 
the polyglutamine sequence in the affected proteins (Wilmot 1998; Bates 2002). The 
strongest evidence for this conclusion is that expression of a CAG repeat expansion 
within the context of the unrelated protein hprt causes a similar neurodegenerative 
disease (Ordway, Tallaksen-Greene et al. 1997). This suggests that expansion of 
polyglutamine itself is responsible for the neurodegeneration, and further suggests that 
the protein context of different disease proteins probably play roles in defining the 
specificities of different diseases. Recent studies in HD suggest that some partial loss of 
4 
function of the huntingtin protein may also contribute to disease onset (Cattaneo, 
Rigamonti et al. 2001). Nonetheless, polyglutamine diseases often present as a dominant 
inherited pattern, except for SBMA (this will be explained in SBMA section) (Zoghbi 
and Orr 2000). In the other trinucleotide repeat diseases, mutations occur in 3 , 5 
untranslated regions (UTR) or introns; these mutations interfere with normal gene 
transcription or translation and result in partial or complete depletion of the gene products. 
This usually leads to a loss of function mutation and presents as a recessive inheritance 
pattern (Reddy and Housman 1997). In Figure 1, the different trinucleotide repeat 
diseases are illustrated according to where in the gene the mutation occurs.  
The discovery of trinucleotide repeats expansion in 1991 (La Spada, Wilson et al. 
1991) revealed a new mutational mechanism, called dynamic mutation (or genetic 
instability), which is characterized by distinct inheritance features, such as increasing 
penetrance or anticipation (increasing disease severity and decreasing age of onset in 
successive generations due to increasing lengths of trinucleotide repeats in an affected 
family) (Wilmot 1998; Usdin and Grabczyk 2000). Mechanisms of repeat expansion are 
poorly understood. Based on in vitro bacteria and yeast studies, mechanisms of repeat 
expansion can be explained by invoking aspects of DNA structure, replication and repair 
(Wilmot 1998). First, repetitive DNA can adopt other more stable structures than double 
helix, such as hairpin, triplex and tetraplex (Kovtun and McMurray 2001) and these 
structures stabilize the repeats and interfere with normal DNA replication and repair. 
Second, expansions can occur by strand slippage during DNA replication 
(Schweitzer and Livingston 1999) and/or by misalignment during DNA excision repair  
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Figure 1.  Features of trinucleotide repeat diseases, including polyglutamine 
diseases 
(CGG)n
(CAG)n
(GAA)n (CTG)nMutations: 
Transcription: X X X
Translation: 
No gene product
 
Abnormal protein  
 
No/reduced gene product  
 
Example 
Disease: 
Fragile X
 syndrome 
Polyglutamine 
diseases  
Friendreich 
Ataxia 
Myotonic 
Dystrophy 
6 
(Schweitzer and Livingston 1997) and recombination of DNA strands (Jakupciak and 
Wells 1999). Detailed hypotheses of the expansion mechanism have been reviewed 
(Usdin and Grabczyk 2000; Kovtun and McMurray 2001). 
From clinical and pathological points of view, polyglutamine disease can be 
linked with a large family of neurodegenerative diseases featuring the presence of 
aggregates or inclusion bodies in brain tissue (Taylor, Hardy et al. 2002); these include 
Alzheimers disease, Parkinsons disease, prion diseases, Amyotrophic Lateral Sclerosis 
(ALS) and the tauopathies. The aggregated proteins and the location of these aggregates 
in the brain tissue are different for different diseases (Merlini, Bellotti et al. 2001). At the 
same time, protein misfolding and aggregation can be considered to be fundamental 
problems underlying all these diseases (Taylor, Hardy et al. 2002). Table 2 summarizes 
the aggregation related neurodegenerative diseases. 
None of the nine polyglutamine diseases are curable at the current time. At 
present, the only available medical treatment is the care and supportive therapy that are 
used in the clinic (Kieburtz 2002). Within families, the severity of disease tends to 
increase in successive generations (as described by anticipation, a hallmark of these 
diseases). Offspring tend to inherit even longer repeat expansions (especially through 
paternal transmission) due to the genetic instability imparted by the repeat length 
(Wilmot 1998). Since there are many other known CAG repeats coding for 
polyglutamine containing proteins in the genome that have not been linked to a disease, 
and given that a repeat expansion mutation might occur in virtually any of those proteins, 
one can imagine that there will be more polyglutamine diseases discovered in the future  
7 
 
Table 2.  Protein aggregation and neurodegenerative diseases a 
Disease Disease genes Responsible protein Protein aggregates  
Polyglutamine 
Diseases 
CAG repeat 
expansion lies in 
different genes 
Polyglutamine 
containing proteins 
Neuronal intranuclear 
inclusions (NII) 
Alzheimers 
Disease 
APP, 
Presenilin1, 
Presenilin2 
Aβ/tau Extracellular plagues (by 
Aβ) /intracellular tangles 
(by tau) 
Parkinsons 
Disease 
α-Synuclein, 
Parkin 
 
α-Synuclein Lewy bodies 
ALS SOD1 b SOD1 Bunina bodies 
Prion  Diseases PRNP PrPSc Prion plaques 
Tauopathy tau tau Cytoplasmic tangels 
a The table was modified from (Taylor, Hardy et al. 2002).  
b The relationship of familial ALS involving SOD1 mutations, to other form of ALS, is 
not clear.  
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(Cummings and Zoghbi 2000). The situation is devastating. Hope for curing the disease 
in the future depends on the emergence of a better understanding of the common 
mechanisms of all polyglutamine diseases that will ultimately lead to the discovery for a 
cure. 
In this chapter, I will first introduce each of the nine known polyglutamine 
diseases from historical, epidemiological, clinical, neuropathological, genetic and 
molecular aspects. Then, the diseases will be compared with respect to their similarities 
and differences, in order to bring out the possibility of a unified mechanism behind all of 
the polyglutamine diseases.  The third part will be a review of the discoveries drawn from 
the studies of the existing experimental model systems in polyglutamine disease, with 
brief discussions on the advantages and disadvantages of these models. Lastly, I will 
summarize the various proposed molecular and cellular mechanisms of the polyglutamine 
diseases, including the existing questions and controversies rising out of different studies. 
This will also include a discussion of various cell death mechanisms, including apoptosis, 
necrosis and other cell death mechanisms. This information provides critical background 
for understanding the goals, experimental design and conclusions of the experiments 
described here. 
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 Huntington’s Disease (HD) 
History and epidemiology of HD 
HD was first described in 1872 by Dr. George Huntington as hereditary chorea 
in his paper called On chorea (Huntington 1872). Together with the documentation from 
his father and grandfather, he observed a disease inherited in the successive generations 
of three families in Long Island, NY. HD is the most common and extensively studied 
disease among nine polyglutamine diseases. The prevalence of HD in Caucasians is about 
5-10 per 100,000 individuals (Harper 1992). HD is less common among Asian population 
(1/10 of the Caucasians) and very rare in African population (Harper 2002).   
Clinical manifestations of HD 
The characteristic clinical manifestation of HD is chorea, which is a Greek word 
meaning dance. A more precise clinical definition for chorea is a state of excessive, 
spontaneous movements, irregularly timed, randomly distributed and abrupt (Barbeau, 
Duvoisin et al. 1981). In the early state of HD, chorea can be presented as fasciculations 
(muscular twitching of contiguous groups of muscle fibers) of facial muscles or random 
twitching of the fingers and toes. As the disease progresses, it will affect larger 
movements of the arms, legs and whole body, and present as dance-like gait and 
ballismus (a type of involuntary movement affecting the proximal limb musculature, 
manifested as flinging movements of the extremity) in some severe cases. Other than 
chorea, there are also other motor dysfunctions present, such as dystonia (disordered 
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muscle tone), hyperactive reflexes and speech abnormalities (Kremer 2002). Along with 
these movement disorders, HD patients often have different degrees of cognitive and 
psychiatric symptoms, such as memory loss and personality changes (Craufurd and 
Snowden 2002).  HD is mainly a midlife-onset (40 ±10 years of age) disease, but can 
start at any age (2-80 years of age).  HD is ultimately fatal with an average of 15-17 years 
after the onset of symptoms (Kremer 2002). 
Neuropathology of HD 
The neuropathological hallmark of HD at the macroscopic level is the striking 
atrophy of the neostriatum, in which the loss of caudate nucleus is the most dramatic: up 
to 95% of the neurons of the caudate nucleus are lost in the late stage of HD, 
accompanied by an overall brain atrophy (Heinsen, Strik et al. 1994; Gutekunst, Norflus 
et al. 2002). Figure 2 is a postmortem brain specimen showing the brain atrophy at the 
different stages of HD compared to a normal aged control brain (Myers 1998). Figure 3 is 
a schematic illustration of the brain pathology of HD and some other polyglutamine 
diseases derived from a review of Bates et al. (Bates 2002). Brain weight is often reduced 
by about 10-20% in HD compared to a normal control brain measured at autopsy 
(Gutekunst, Norflus et al. 2002).  
At the cellular level, it has been found that the medium size striatal neurons in 
postmortem HD brain are selectively depleted compared to large staital neurons (Heinsen, 
Strik et al. 1994). These medium spiny neurons are inhibitory projection neurons of 
striatum and the major component (95%) of the caudate nucleus (Gutekunst, Norflus et al. 
2002). This selective loss of medium striatal neurons may underlie the chorea movement 
11 
 
    
    
 
Figure 2. Comparasion of HD brain atrophy with normal aged control brain.  
Figures shown here are the hemicoronal sections of postmortem brain from (I) normal 
aged control, (II) early state of HD (grade 2), (III) mid state of HD (grade 3) and (IV) late 
state of HD (grade4). One can appreciate from these figures how dramatic the brain 
atrophy in HD is. Figure is taken from (Myers 1998). 
I 
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Figure 3. Schematic depiction of the brain pathology of 5 polyglutamine diseases.   
The affected areas are indicated by shading (the darker, the more severely affected). 
From (Bates 2002). 
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in patients (Heinsen, Strik et al. 1994). Organs other than brain are largely unaffected, 
even though the HD gene is expressed universally (Sharp, Loev et al. 1995).  
At the subcellular level, in both striatum and cortex, neuronal intranuclear 
inclusion (NII) bodies are characteristic to HD (DiFiglia, Sapp et al. 1997).  NIIs are 
protein aggregates made up mainly of N-terminal fragments of mutant huntingtin. 
Ubiquitin, α-synuclein, cAMP-response element binding protein [(CREB)-binding 
protein or CBP] have also been shown to be recruited into the aggregates (DiFiglia, Sapp 
et al. 1997) (Nucifora, Sasaki et al. 2001). NIIs are large, 3-5um in diameter, and mostly 
round in shape, with only 1 or 2 per nucleus (DiFiglia, Sapp et al. 1997). Figure 4 is an 
electron micrograph showing the NII in the neuronal nucleus of a postmortem HD brain 
(DiFiglia, Sapp et al. 1997). Extra-nuclear aggregates, such as perinuclear (on the nuclear 
exterior surface) or neuropil (axonal, dendritic and synaptic) aggregate, can also be found 
in the HD brain (Gutekunst, Norflus et al. 2002). They are usually smaller in size and 
larger in number compare to NII. Studies have shown that some of these aggregates can 
be stained with Congo red and exhibit birefringence under polarized light microscope, 
and also possess filamentous ultra-structures under electron microscopy (McGowan, van 
Roon-Mom et al. 2000), suggesting it is an amyloid-like structure. Increased DNA 
fragmentation detected in HD striatal neurons suggests that apoptosis is involved in the 
cell death mechanisms (Butterworth, Williams et al. 1998), while gliosis has also been 
observed near affected neurons (Gutekunst, Norflus et al. 2002), suggesting that necrosis 
may also be involved. 
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Figure 4. Electron micrograph of the NII in the nucleus of postmortem HD brain. 
(Taken from (DiFiglia, Sapp et al. 1997)) 
 
NII 
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Genetics of HD 
The inheritance pattern for HD is clearly autosomal dominant (Gusella and 
MacDonald 1995).  In 1983, the HD gene was mapped to chromosome 4p16.3 by genetic 
linkage analysis. After 10 years of molecular genetic analysis, the HD gene and mutation 
were finally revealed in 1993 by a large group effort (Huntingtons Disease Collaborative 
Research Group) (Myers, MacDonald et al. 1993). The HD gene is about 185 kb and 
contains 67 exons. An expanded CAG repeat was found in exon 1 of HD gene in HD 
patients, coding for a polyglutamine tract near the N-terminus of the predicted gene 
product, called huntingtin. Unaffected individules have a repeat length ranging from 6 to 
39, while HD patients have repeat lengths ranging from 36 to over 200 (Bates 2002). 
Protein product and normal function 
Huntingtin is a large (around 350 kD) cytoplasmic protein of unclear function. It 
is widely expressed throughout the brain and in other tissue. In brain, huntingtin is 
associated with microtubules in dendrites and synaptic vesicles, suggesting it may have 
some function in synaptic transportation and transmission (Sharp, Loev et al. 1995).  
There are two proteins known to interact with normal huntingtin. One is huntingtin-
associated protein 1 (HAP1) (Li, Li et al. 1995; Peters and Ross 2001) and the other is 
Huntingtin-interacting protein 1 (HIP1) (Kalchman, Koide et al. 1997; Wanker, Rovira et 
al. 1997). Their functions are not very clear.  Some studies suggest that huntingtin may be 
involved in intracellular trafficking, vesicle transmission and endocytosis, further 
supporting the hypothesis that huntingtin may be associated with synaptic functions. 
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Recent studies also suggest that wide-type huntingtin may have a role in anti-apoptosis 
by depletion of a possible proapoptotic protein, HIP1 (Hackam, Yassa et al. 2000; 
Rigamonti, Bauer et al. 2000). 
 
Spinal and Bulbar Muscular Atrophy (SBMA) 
History and epidemiology of SBMA 
W.R. Kennedy was the first to described SBMA, in 1968 (Kennedy, Alter et al. 
1968), and the disease is often called Kennedys Disease. In 1991, an expansion of a 
CAG repeat in the first exon of the androgen receptor gene was identified as the disease 
mutation (La Spada, Wilson et al. 1991). Thus, SBMA was actually the first recognized 
polyglutamine disease. The prevalence of SBMA is very low; an incidence estimate 
hasnt been reported. Gathering the information from OMIM (Online Mendelian 
Inheritance in Man at www.ncbi.nlm.nih.gov), there are less than 200 reported families 
diagnosed with SBMA world wide, from Finland, Sweden, Norway, Denmark, Germany, 
Belgium, Italy, Japan, Australia and Canada. 
Clinical and neuropathological features 
SBMA presents an X-link recessive inheritance pattern, with males predominantly 
affected. Female carriers exhibit mild symptoms under careful examination (Sobue, 
Hashizume et al. 1989). Despite the recessive inheritance pattern, SBMA is a dominant 
mutation at the molecular and cellular level. It is probably due to (a) random inactivation 
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of the X-chromosome that some heterozygous females dont have severe symptoms; (b) 
even if mutant AR is expressed in the female, the level is very low and may have little or 
no effect (Zoghbi and Orr 2000). The onset of the symptoms usually starts at around 30-
50 years of age (there are also extreme cases reported as early as 12 years or late as 84 
years), with muscle cramps at an early stage developing into muscle weakness and 
atrophy in proximal muscles like arms and shoulders. Fasciculation can occur in tongue 
and jaw muscles, with later development into dysarthria (difficulty in articulating words, 
caused by impairment of the muscles used in speech) (MacLean, Warne et al. 1996). In 
the male SBMA patients, testicular atrophy and subsequently infertility (described as 
androgen insensitivity) can also be observed, suggesting there is some partial loss of 
function (Zoghbi and Orr 2000). As the disease name suggests, the neuropathology is 
mainly the loss of motor neurons in the spinal cord and brain stem bulbar region (see 
Figure 3). The degeneration of anterior horn neurons in the spinal cord is severe, while 
the posterior horn cells are well preserved. Loss of primary sensory neurons in dorsal root 
ganglia has also been reported.  The muscle atrophy is mainly the result of chronic 
denervation due to the loss of anterior horn spinal neurons (Zajac 1998). NIIs made of 
mainly ubiquitinated full length or cleaved AR are presented in motor neurons of SBMA 
patients (Li, Miwa et al. 1998).  
Androgen receptor gene and protein product 
The androgen receptor (AR) gene, located on chromosome Xq11-12, is over 
100kb in size, and contains 8 exons coding for a protein of 919 amino acids (Lubahn, 
Joseph et al. 1988). The CAG repeat is located in the first exon of the AR gene. While the 
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normal repeat length is 9-33, in SBMA it expands to 38-65. AR is a steroid hormone 
receptor and a transcription factor that responds to androgen binding (Lumbroso, 
Lobaccaro et al. 1997). The structure of the AR protein is composed of a hormone 
binding site, a DNA binding domain, a nuclear localization signal (NLS) and a 
transcriptional activation region (Zajac 1998). The polyglutamine tract is in the N-
terminus of AR. The complete depletion of polyglutamine does not affect the normal 
transcriptional function of AR; expanded polyglutamine slightly decreases AR activity 
and may account for the androgen insensitivity in SBMA. Complete loss of AR results in 
testicular feminization but not SBMA (Zoghbi and Orr 2000). 
 
Dentatorubral – Pallidoluysian Atrophy (DRPLA) 
History and epidemiology of DRPLA 
Sporadic cases of DRPLA were originally described by Smith et al. (Smith 1975), 
while the hereditary form of DRPLA was first described by Naito et al. in Neurology in 
1982 (Naito and Oyanagi 1982). DRPLA is mainly seen in Japan, with a prevalence of 
around 6 in 1,000,000 (Kondo 1998) A few cases of DRPLA have been reported outside 
of Japan, in Europe (Nielsen, Sorensen et al. 1996) and in the United States (Potter, 
Meyer et al. 1995; Potter 1996). In addition, Haw River Syndrome, described in an 
African-American family residing near Haw River in North Carolina, was later found to 
be caused by the same mutation of DRPLA (Vance 1998) and is now considered to be 
another form of DRPLA. The mutation of the gene responsible for DRPLA was 
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discovered by two independent groups in 1994 (Koide, Ikeuchi et al. 1994; Nagafuchi, 
Yanagisawa et al. 1994). 
Clinical and neuropathological feature 
The onset of DRPLA can range from 1 to 74 years of age, with a mean of about 
27-33. Clinical features of DRPLA vary in each patient, with key features including 
ataxia (failure of muscular coordination, irregularity of muscular action), chorea and 
dementia, making the disease easily confused with HD prior to characterization of the 
mutation. In addition, some patients may have myoclonus (twitching or spasm of a 
muscle or a group of muscles), tremor, epilepsy (neurological disorders characterized by 
sudden recurring attacks of motor, sensory, or psychic malfunction with or without loss 
of consciousness or convulsive seizures) and psychiatric symptoms (Naito and Oyanagi 
1982). The disease is usually fatal with a mean period between onset and death of 12 
years (Kondo 1998). The major neuropathology of DRPLA is, as the disease name 
suggests, a combined atrophy in the dentatorubral and pallidolusian systems, including 
neuronal loss in the cerebral cortex, globus pallidus, striatum, cerebellar cortex, the 
dentate nucleus and the subthalamic and red nuclei, as shown in Figure 2. Gliosis and 
even calcification often accompany neuronal loss in some severe cases (Kondo 1998). 
Mutation and gene products 
The gene for DRPLA is on 12p13.31 and spans 20kbp with 10 exons. The CAG 
repeat is located in exon 5, 1462bp downstream from the start codon (Koide, Ikeuchi et al. 
1994; Nagafuchi, Yanagisawa et al. 1994). The normal range for the repeat is about 3-35, 
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while the expanded repeats in DRPLA range between 49 and 88 (Bates 2002).  The gene 
codes for a protein, called atrophin-1, containing 1185 amino acids (Yazawa, Nukina et al. 
1995). The function of atrophin-1 is not clear. Atrophin-1 contains a proline-rich region 
and several arginine-glutamic acid (RE) repeats, which may have some function in 
protein interaction (Yanagisawa, Bundo et al. 2000). The drosophila homolog of 
atrophin-1 has been suggested to have transcriptional corepressor roles in multiple 
developmental processes of drosophila (Zhang, Xu et al. 2002). Atrophin-1 is widely 
expressed and mainly located in the cytoplasm of the neurons (Schilling, Wood et al. 
1999). Nuclear inclusion bodies containing mutant atrophin-1 have been found in the 
affected neurons (Zoghbi and Orr 2000). 
 
The Sprinocerebellar Ataxias  
Spinocerebellar ataxias (SCAs), also called the autosomal dominant 
spinocerebellar ataxias (ADCAs), are a class of heterogeneous neurodegenerative 
disorders with different degrees and combinations of progressive degeneration of the 
cerebellum, brain stem and spinal cord, resulting in different degrees of progressive 
cerebellar ataxias (Stevanin, Durr et al. 2000). It was impossible to classify and 
distinguish each of the diseases in this family before the genetic markers of each disease 
were known. Based on clinical manifestations, ADCAs have been divided into three 
groups since 1983 (Klockgether and Evert 1998). With the discovery of the genes and 
mutations, each of ADCAs was given an individual name from SCA1 to SCA17. The 
overall prevalence of all the ADCAs together has been estimated to be about 10/100,000 
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(Stevanin, Durr et al. 2000). Certain SCAs may have very high prevalence in certain 
areas due to the founder effect; for example, SCA2 is 4/10,000 in Cuba, where the 
disease was discovered (Orozco, Estrada et al. 1989; Gispert, Nothers et al. 1993). In the 
17 known SCAs, 6 have been discovered to feature an expansion of a CAG repeat in the 
respective genes as the mutational mechanism of disease. These are SCA1, 2, 3, 6, 7, and 
17 (Stevanin, Durr et al. 2000). They will be introduced individually below. 
 
Spinocerebellar Ataxia 1 (SCA1) 
History of SCA1 
In the early days, SCA1 was often confused with Friedreichs ataxia based on the 
clinical findings. In 1974, Yakura described a dominant inherited ataxia that later became 
known as SCA1 (Yakura, Wakisaka et al. 1974). By classic linkage analysis in a large 
family, Jackson et al later mapped the gene for the disease to chromosome 6p 
(Subramany SH 1998). In 1993, the gene mutation for SCA1, an in-frame expanded CAG 
repeat, was reported by Orr et al. (Orr, Chung et al. 1993) 
Clinical manifestations and neuropathology 
SCA1 is an autosomal dominant, progressive neurodegenerative disorder with the 
key clinical symptoms including ataxia, dysarthria, motor dysfunction, dysphagia 
(difficulty in swallowing) and amyotrophy (a type of neuropathy that causes muscle 
weakness and wasting). The age of onset of the disease ranges from 6 to 74 with a mean 
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age of around 35. The time between clinical presentation and death ranges from12 to 38 
years. The mean death age has been estimated at 54 (Subramany SH 1998). The 
neuropathology is characterized by cerebellar atrophy with severe loss of Purkinje cells. 
Neurodegeneration has also been found in inferior olive neurons, dentate nucleus and 
brain stem (see Figure 3). At the cellular level, a single, large nuclear inclusion body is 
often observed in the Purkinje cells and brain stem neurons in SCA1 postmortem brain 
specimens (Cummings, Orr et al. 1999). 
Gene product and protein function 
SCA1 gene is located on chromosome 6p23, spans 450 kb of DNA and is 
composed of nine exons (Banfi, Servadio et al. 1994). The CAG repeat lies in the coding 
region of the gene and codes for a polyglutamine tract. In unaffected individules, the 
repeat length is about 6-44, with 1-3 CAT (coding for histidine) interruptions in the 
longer repeats (over 21). In SCA1, the repeat usually contains 39-83 pure CAG. The 
CAT codons in normal genes appear to play a role both in suppressing genetic repeat 
expansions and, in longer, normal range repeats, suppressing aggregation of the gene 
product (Matsuyama, Izumi et al. 1999). The gene product of SCA1 is a protein called 
ataxin-1, which is an 816-amino acid protein with a molecular weight of 87 kD (Banfi, 
Servadio et al. 1994). The polyglutamine tract is located at amino acid number 197. 
Ataxin1 is expressed both in CNS and peripheral tissues including heart, skeletal muscle, 
liver, pancreas and lung (Servadio, Koshy et al. 1995). The expression level in CNS is 2 
to 4 times higher than that of other tissue, suggesting a neuronal function of the protein. 
In brain, the expression of SCA1 does not seem to differ qualitatively from region to 
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region. Ataxin1 has been found in both the cytoplasm and nucleus in the neurons, but 
only in the cytoplasm in the peripheral tissues (Servadio, Koshy et al. 1995). The exact 
function of ataxin1 is largely unknown. Studies in gene knock-out mice suggest it may 
have some function in learning and memory (Matilla, Roberson et al. 1998). In vitro 
studies show that ataxin1 has RNA-binding ability and may thus have a role in RNA 
metabolism at the cellular level (Yue, Serra et al. 2001). 
 
Spinocerebellar Ataxia 2 (SCA2) 
History of SCA2 
The clinical description of SCA2 was first documented in a European family by 
Boller and Segarra in 1969 (Boller and Segarra 1969). SCA2 represent 13-15% of ADCA 
and the majority of SCA1 patients are from Caucasian ancestry.[Pulst, 1998 #2358] In 
1993, the SCA2 gene was mapped to chromosome 12 (Gispert, Twells et al. 1993) by 
linkage analysis in a large Cuban kindred. Soon thereafter, the SCA2 gene was 
discovered and an expansion of its CAG repeat was identified as the disease causing 
mutation by positional cloning (Pulst, Nechiporuk et al. 1996), and by a new method 
called DIRECT (Direct Identification of Repeat Expansion and Cloning Techniques) 
(Sanpei, Takano et al. 1996). 
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Clinical manifestation and neuropathology 
The clinical manifestations of SCA2 are similar to other SCAs, with ataxia, 
dysarthria and other spinocerebellar symptoms, in addition to which eye movement 
abnormalities have often been found in some patients.[Pulst, 1998 #2358] The age of 
onset ranges from 2 to 65 years.[Pulst, 1998 #2358] The major neuropathology findings 
are atrophy in the cerebellum and brain stem with severe loss of cerebellar Purkinje cells 
and granule cells. Neurodegeneration can also be found in the frontotemporal lobes and 
substantia nigra. In SCA2 brains, cytoplasmic aggregates and a diffuse pattern of nuclear 
staining (that might be microaggregates) have been found in the affected brain region 
(Koyano, Uchihara et al. 1999; Huynh, Figueroa et al. 2000). 
Gene, mutation and protein 
The SCA2 gene, located on chromosome 12q24.1, contains 25 exons and spans 
approximately 130 kb. The CAG repeat, interrupted by two CAA codons, is located in 
exon 1. The normal repeat size ranges from 13 to 33, while the SCA2 length ranges from 
32 to over 200; the particularly long repeats cause severe infantileonset SCA2 (Mao, 
Aylsworth et al. 2002). The SCA2 gene is widely expressed, including in the brain, heart, 
placenta, liver, skeletal muscle and pancreas (Imbert, Saudou et al. 1996). The gene 
product, called ataxin-2, is a 140kD protein with a polyglutamine stretch near the N-
terminus. Normal ataxin-2 is located diffusely in the cytoplasm.[Pulst, 1998 #2358] The 
function of ataxin-2 is not clear, but it may be involved in developmental regulation, as 
studies in C-elegans identified an orthologue of ataxin-2 that is important for early 
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embryonic patterning (Kiehl, Shibata et al. 2001); and the mouse SCA2 gene homologue 
is expressed strongly in early embryogenesis (Nechiporuk, Huynh et al. 1998). Recent 
studies suggest that it might have some function in RNA splicing, since it is co-localized 
with a novel protein A2BP1 containing RNA-binding motifs (Shibata, Huynh et al. 2000).  
 
Spinocerebellar Ataxia 3 (SCA3) 
History of SCA3 
SCA3 is also called Machado-Joseph Disease (MJD), named after the Machado 
and Joseph families, who were first reported with the clinical features of SCA3 in 1972 
and 1976 respectively (Nakano, Dawson et al. 1972; Rosenberg, Nyhan et al. 1976). The 
prevalence of SCA3 is about 30 to 80 percent of the prevalence of all SCAs in different 
countries (Bates 2002). The SCA3 gene and mutation was discovered in 1994, based on 
linkage analysis in a Japanese SCA3 family (Kawaguchi, Okamoto et al. 1994) and a 
cytogenetic method (FISH) with a putative fragment probe (Takiyama, Nishizawa et al. 
1993; Takiyama, Oyanagi et al. 1994). 
Clinical manifestation and neuropathology 
The major clinical manifestations of SCA3 include ataxia, dysarthria, 
Parkinsonism (a group of neurological disorders characterised by decreased muscular 
activity, tremor and muscular rigidity), dystonia and ophthalmoplegia (loss or impairment 
of the motor function of the ocular muscles) (Stevanin, Durr et al. 2000). The age of 
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onset of SCA3 varies from the teens to 60 years of age. The major neuropathological 
features are the degeneration of basal ganglia, globus pallidus, brain stem motor neurons, 
spinal cord and dentate nucleus (Stevanin, Durr et al. 2000), shown in Figure 2. The 
degeneration is mild in cerebellar Purkinje cells. In SCA3 patients, nuclear aggregates 
containing ataxin3, ubiquitin, and various components of the proteasome and cellular 
chaperones have been detected in the affected regions of brain (Paulson, Perez et al. 
1997). 
Gene, mutation and protein 
The SCA3 gene is located on chromosome 14q32.1. The gene of SCA3 contains 
48,240 bp and to contain 11 exons (Ichikawa, Goto et al. 2001). The CAG repeat lies in 
the coding sequence near the 3 end of the gene. Normal repeat lengths range from 3 to 
40. In SCA3, the repeat length is 54-89 (Bates 2002). The gene product of SCA3 is a 
protein called ataxin-3, which is a 42kDa protein with unknown function. Ataxin-3 is 
widely expressed throughout the body and has no regional specificity in brain (Paulson, 
Das et al. 1997). In the neurons, ataxin-3 has been detected in both the cytoplasm and the 
nucleus and contains a putative nuclear transportation signal (NLS) near the 
polyglutamine stretch (Tait, Riccio et al. 1998). A recent yeast two-hybrid study revealed 
two human homologs of the yeast DNA repair protein RAD23 interacting with ataxin3, 
suggesting a nuclear function (Wang, Sawai et al. 2000). 
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Spinocerebellar Ataxia 6 (SCA6) 
History of SCA6 
 The discovery of SCA6 was by an unusual route compared to that of the previous 
6 polyglutamine diseases. It was already known that a polymorphic CAG repeat lay 
within the human alpha 1A voltage-dependent calcium channel subunit (CACNA1A) 
(Ophoff, Terwindt et al. 1996). In 1997, Zhuchenko et al analyzed the genotypes of a 
large ataxia patient group and 8 unrelated families, whom were found to contain 
moderate CAG expansions in CACNA1A (Zhuchenko, Bailey et al. 1997). Since 1997, 
more cases of SCA6 have been reported from Japan and German (Gomez, Thompson et 
al. 1997; Schols, Kruger et al. 1998). 
Clinical manifestation and neuropathology 
  The clinical features of SCA6 include slowly progressive cerebellar ataxia, 
dysarthria, nystagmus (an involuntary, rapid, rhythmic movement of the eyeball) and 
vibratory sensory loss (Zhuchenko, Bailey et al. 1997). The age of onset varies from 20 to 
66 years with an average of 45 years of age. SCA6 usually progresses over a 20 to 30 
year period before its lethal end stage (Zhuchenko, Bailey et al. 1997). 
Neurophathologically, the cerebellar atrophy with the loss of Purkinje cells is severe, the 
brainstem shows mild atrophy, and moderate degeneration can be found in dentate 
nucleus and inferior olive. Both nuclear and cytoplasmic aggregates have been found in 
cerebellar Purkinje cells (Ishikawa, Owada et al. 2001). 
28 
Gene, mutation and protein 
The CACNA1A gene is located on chromosome 19p13 and covers 300 kb with 47 
exons. The CAG repeat lies in the coding region near the 3 end. The normal repeat size 
is 4-18 and in SCA6 the repeat length ranges from 21 to 33. It is an interesting exception 
among the polyglutamine diseases, with the threshold between normal and disease 
occurring in a repeat length range about one half that found in the other diseases (Bates 
2002). CACNA1A gene codes for the alpha 1A subunit of voltage-gated calcium 
channels type P/Q, whose function is to control neurotransmitter release in synapses 
(Dunlap, Luebke et al. 1995). CACNA1A is expressed widely in the brain with the 
highest expression level in cerebellum (Fletcher, Lutz et al. 1996). Because of the 
important role of CANA1A in the neurons, the pathogenesis of SCA6 may be more 
complex than other polyglutamine diseases and the expansion of polyglutamine in the 
protein may gain more toxicity due to the location and the high local concentration, 
which may explain why the repeat length for disease onset is lower than other 
polyglutamine diseases (Zoghbi and Orr 2000). 
 
Spinocerebellar Ataxia 7 (SCA7) 
 History of SCA7 
 SCA7 is distinguished from the other spinocerebellar ataxias due to the 
characteristic retinal degeneration that is associated with neurological dysfunction in this 
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disease (David, Durr et al. 1998). In 1995, the gene for SCA7 was mapped on 
chromosome 3p by linkage analysis (Holmberg, Johansson et al. 1995). By a novel 
technique called repeat expansion detection (RED), which detects repeat expansions 
directly from genomic DNA, the mutation of SCA7 was confirmed to be CAG repeat 
expansion in 1996 (Lindblad, Savontaus et al. 1996). In 1997, the SCA7 gene was 
discovered by positional cloning based on the previous information (David, Abbas et al. 
1997). 
Clinical manifestation and neuropathology 
  Clinically, SCA7 contains both the classic features of SCAs including ataxia, 
dysarthria, hyperreflexia (exaggeration of reflexes), and ophthalmoplegia (ocular 
muscular dysfunction due to the impairment of motor neurons that control the ocular 
muscles), as well as progressive vision defects, starting from blue-yellow 
dyschromatopsia (a condition in which the ability to perceive colors is abnormal) at the 
initial stages and evolving to complete blindness in the end (David, Durr et al. 1998). The 
age of onset of SCA7 varies from 1 to 70 years depending on the CAG repeat length with 
a mean at 29. The neuropathological features include atrophy in cerebellum and neuronal 
loss in inferior olive, dentate nucleus and cranial nerve nuclei.  Retinal pathology 
includes loss of photoreceptors, ganglion and bipolar cells. SCA7 was reviewed in 
(Martin, Van Regemorter et al. 1999). Intranuclear intrabodies have been detected in 
several parts of the brain (Holmberg, Duyckaerts et al. 1998). 
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Gene, mutation and protein 
The SCA7 gene is located on chromosome 3p12-13. The gene contains a 2727 bp 
open reading frame made up of 13 exons. The CAG repeat is located near the 5 end of 
the gene. The repeat length in unaffected individules is 4-35; it is 37-306 in the SCA7 
patients (David, Abbas et al. 1997; Bates 2002). The gene encodes an 892 amino acid 
long (130kD) protein of unknown function, named ataxin-7 (David, Durr et al. 1998). 
Ataxin-7 is widely expressed in CNS and other tissue (Jonasson, Strom et al. 2002). It 
contains a nuclear localization signal (NLS), indicating a nuclear function of the protein. 
Ataxin-7 has also been found to be co-localized with an endoplasmic reticulum marker, 
BiP, a molecular chaperone, which functions to protect proteins from aggregation during 
assembly (Martin, Van Regemorter et al. 1999). 
  
Spinocerebellar Ataxia 17 (SCA17) 
History of SCA17 
 SCA 17 was discovered very recently. In 1999, Koide et al described (Koide, 
Kobayashi et al. 1999) a neurological disorder in a single Japanese individual caused by 
CAG expansion in the TATA-binding protein (TBP), raising the question is this a new 
polyglutamine disease?. In 2001, six additional families (two German and four Japanese) 
were reported individually with CAG repeat expansion mutations in TBP associated with 
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neurodegeneration (Nakamura, Jeong et al. 2001; Zuhlke, Hellenbroich et al. 2001). Thus, 
SCA17 was discovered. 
Clinical manifestation and neuropathology 
The clinical features of SCA17 include ataxia, impaired pyramidal, 
extrapyramidal and autonomic systems, and severe intellectual impairment. The age of 
onset ranges from 19 to 48 years (Fujigasaki, Martin et al. 2001; Nakamura 2001). The 
postmortem brain tissue from one patient showed shrinkage and moderate loss of small 
neurons, with gliosis predominantly in the caudate nucleus and putamen and similar but 
moderate changes in the thalamus, frontal cortex, and temporal cortex. Moderate Purkinje 
cell loss and an increase of Bergmann glia were seen in the cerebellum (Fujigasaki, 
Martin et al. 2001). Immunocytochemical analysis performed with anti-ubiquitin and 
anti-TBP antibodies showed neuronal intranuclear inclusion bodies (Fujigasaki, Martin et 
al. 2001). 
Gene, mutation and protein 
TBP gene is located on chromosome 6q27. It normally contains a 25-44 CAG 
repeat, while in SCA17, it contains a 46-63 repeat (Fujigasaki, Martin et al. 2001; 
Nakamura 2001). The function of normal TBP is a DNA-binding subunit of RNA 
polymerase II transcription factor D (TFIID) (Peterson, Tanese et al. 1990), which is 
essential for the expression of almost all of the protein-encoding genes in the cells 
(Rowlands, Baumann et al. 1994). 
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Summary on the similarities and differences in polyglutamine diseases 
 The common features of the diseases are summarized as following: 
1. Genetically the 9 diseases have a similar mutational basis: expansion of CAG 
repeats in the coding sequences. The repeat length cutoff for each of the disease is 
around 36-40 [except SCA6 (20) and SCA17 (46)] (Zoghbi and Orr 2000; Bates 
2002). The diseases are mostly dominantly inherited (except for SBMA, explained 
in SBMA section). Other mutations in the same genes, such as missense mutations, 
nonsense mutations or completely depletion of the genes, which result in loss of the 
normal function of the gene products, cause different diseases, not polyglutamine 
diseases. For example, loss of AR gene result in testicular ferminization rather than 
neurodegeneration (SBMA) (Pinsky, Trifiro et al. 1992). Gene knockout mice 
models provide further evidence for the gain of a toxic function by the expanded 
polyglutamine sequence. However, recent studies have also suggested that at least in 
some cases there may be some combinations of gain of function along with the loss 
of the normal functions of the genes in the polyglutamine diseases (Lieberman and 
Fischbeck 2000; Cattaneo, Rigamonti et al. 2001). 
2. The epidemiology of each disease reveals regional differences. This has been 
proposed to be due to the founder effect since many of the different families with 
certain polyglutamine diseases can be traced back to a common ancestor (Stevanin, 
Cassa et al. 1995; Wakisaka, Sasaki et al. 1995; Tanaka, Doyu et al. 1996; 
Didierjean, Cancel et al. 1999; Stevanin, David et al. 1999; Harper 2002).  
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3. Clinically, the diseases are exclusively neurodegenerative diseases: mid-life onset, 
progressive for about 10-30 years and ultimately fatal. Despite the wide expression 
of the mutated genes in most of the tissues in the body, neuronal system is the target 
for the diseases. The disease severity directly correlates with CAG repeat length, 
while the age of onset shows an inverse relationship with the repeat length. Massive 
expansions of polyglutamine result in severe cases of infantile and juvenile diseases 
with onset at very early ages, which progress very fast to death (Bates 2002). 
4. From the neuropathological point of view, selected areas (with some overlap) of the 
brain in each disease show atrophy and neuronal loss as described above. The brain 
atrophy can be very dramatic in the late stage, due to massive neuronal loss. Again, 
the selective vulnerabilities of different subsets of the neurons in each disease are 
lost when massive CAG expansion occurs. The characteristic neuronal intranuclear 
inclusions (NII) are presented in most affected brains. Cytoplasmic aggregates have 
also been detected in HD, SCA2, and SCA6 (Bates 2002). 
5. The gene products of the 9 polyglutamine disease are proteins with no homologies 
to each other except for their polyglutamine sequences. The functions of the proteins 
are largely unknown, except that AR and TBP are transcriptional factors and ataxin-
6 is a calcium channel subunit. The cellular locations of the proteins can be either 
cytoplasmic or nuclear, while NII made of mutated proteins have been found in most 
of the diseases. The nine polyglutamine disease genes and gene products are 
compared and summarized in Tables 3 and 4. 
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Table 3. Summary on polyglutamine disease genes and gene products 
Disease Gene 
locus 
Normal 
/expanded 
CAG repeat 
Gene 
product 
Protein size/ location 
of polyglutamine(aa#) 
Molecular 
weight 
(kD) 
HD 4p16.3 6-39/36-200 huntingtin 3144/18 348 
SBMA Xq11-12 9-33/38-65 AR 918/58 104 
DRPLA 12p13.31 3-35/49-88 Atrophin1 1184/474 190 
SCA1 6p23 6-44/39-83 Ataxin1 816/197 87 
SCA2 12q24.1 13-33/32-200 Ataxin2 1313/166 145 
SCA3 14q32.1 3-40/54-89 Ataxin3 359/292 46 
SCA6 19p13.1 4-19/20-33 CACNA1A 2410/2328 280 
SCA7 3p12-13 4-35/37-306 Ataxin1 893/30 95 
SCA17 6q27 25-44/46-63 TBP 339/58 38 
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Table 4. Comparison of the cellular localizations of polyglutamine proteins and 
aggregates in different diseases and the involvement of proteolytic processing  
Disease Normal protein location Aggregate location Proteolytic cleavage  
HD cytoplasm Nucleus & cytoplasm yes 
SBMA nucleus nucleus yes 
DRPLA cytoplasm nucleus yes 
SCA1 nucleus nucleus no 
SCA2 cytoplasm Nucleus & cytoplasm yes 
SCA3 cytoplasm nucleus no 
SCA6 membrane Nucleus & cytoplasm unknown 
SCA7 nuclear nucleus yes 
SCA17 nucleus nucleus unknown 
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In summary, the common features presented by all of the polyglutamine diseases 
suggested a unified disease mechanism. This mechanism is centered in the expansion of 
polyglutamine tracts in the respective proteins in these different diseases. 
 
Experimental model systems 
 Because the polyglutamine diseases are neurodegenerative diseases, it is 
impossible to get tissues directly from patients at an early stage of disease progression. 
Postmortem brain tissue represents the late stage of the disease pathogenesis and can only 
provide information that contains a mixture of early events and late events (that may be 
the results of an early event). This makes it particularly important to obtain model 
systems to facilitate research in discovering a cure. Indeed, a large variety of mouse, 
invertebrate, cellular and in vitro model systems have been established to study these 
diseases. Different model systems have both advantages and disadvantages. Sometimes 
they do not agree with each other on the very fundamental issues, like the toxicity of the 
polyglutamine aggregates. But the experimental models are invaluable in contributing to 
our understanding of the possible molecular and cellular mechanisms of the diseases. 
Here, I will briefly summarize the findings drawn from the experimental model systems 
with the focus on HD, since it the most intensively studied. The detailed mechanisms will 
be summarized in the section of molecular and cellular mechanism of the diseases. 
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Mouse models 
The mouse model systems can be grouped into three different categories: (1) knock-
out, which is the depletion of the mouse homolog of the gene; (2) transgenic model, 
which is expression of exogenous human polyglutamine containing gene, either full 
length or truncated; (3) knock-in, which uses gene-target strategies to replace the 
polyglutamine sequences in mouse homolog genes with the expanded version.  
A mouse huntingtin homolog has been identified, named Hdh, which is 86% 
identical to the human at the DNA level and 91% identical at the protein level, but with 
only 7 polyglutamines compared to 6-36 polyglutamine in normal human (Barnes, Duyao 
et al. 1994). The extents of homology of all polyglutamine proteins in different organisms 
are summarized in Table 5. The homozygous hdh gene knock-out mouse is an embryonic 
lethal (Duyao, Auerbach et al. 1995), resulting in elevated apoptotic cell death (Zeitlin, 
Liu et al. 1995), which suggests that huntingtin is important for embryonic development 
and may be involved in an anti-apoptosis pathway. Furthermore, the heterozygous knock-
out mouse is phenotypically normal, suggesting that the disease mechanism for 
Huntingtons disease is most probably due to a gain of function, rather than a loss of 
function (Duyao, Auerbach et al. 1995). Transgenic mice with a fragmented human HD 
gene (often exon1) and an expanded CAG repeat show a progressive neurologic 
phenotype with many of the features of HD, including choreiform movements, tremor, 
seizures and weight loss. These mice usually die earlier than control mice. At the same 
time, the full-length human huntingtin transgenic mouse results in a less severe and later 
onset phenotype, suggesting that the cleavage of the full-length huntingtin is important       
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Table 5. The homology of polyglutamine proteins in different organisms at the 
protein level a. 
Diseases Human  Mouse  Rat  Drosophila  C. elegant  
HD 100% 91 % 90 %  -  - 
SBMA 100% 84 % 85 % 25 % 26 % 
DRPLA 100% 92 % 93 % 26 % 27% 
SCA1 100% 85 % 87 % 23 % 39 % 
SCA2 100% 87 % 25 % 20 % 21 % 
SCA3 100% 26 % 85 %  - 33 % 
SCA6 100% 92 % 91 % 59 % 61 % 
SCA7 100% 21 %  -  - 26 % 
SCA17 100% 98 % 40 % 62 % 55 % 
a Numbers are obtained from NCBI website. 
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for pathogenesis (this will be explained later). The knock-in mice show only mild and 
very late onset phenotype in a long polyglutamine knock-in (150Q) model (Bates, 
Mangiarini et al. 1998). 
Fewer mouse models have been generated for other polyglutamine diseases. 
Together with HD, the mouse models for different diseases are listed in Table 6. Taken 
together, the mouse model systems have successfully reproduced the late onset, 
progressive neurological phenotypes of polyglutamine diseases. Studies on these model 
systems shed light on the disease mechanisms. The findings include: (1) the instability of 
CAG repeat, both gametic and somatic (Bates and Davies 1997; Shelbourne, Killeen et al. 
1999); (2) the disease is mainly due to a gain of toxic function by expanded 
polyglutamine protein, but also contains some of degree of loss of normal function of the 
proteins due to the expansion of polyglutamine (Duyao, Auerbach et al. 1995); (3) the 
processing of the full length protein is the first step of the pathogenesis and very 
important for the region selectivity of different diseases (Bates, Mangiarini et al. 1998); 
(4) neuronal dysfunction, including mitochondrial, presynaptic and synaptic disruption, 
occurs at a very early stage, which may account for the early symptoms of the 
polyglutamine diseases, and then progresses to neuronal death (Hodgson, Agopyan et al. 
1999); (5)  Gene expression pattern changes have been revealed by gene expression 
microarray studies (Luthi-Carter, Strand et al. 2000); (6) Polyglutamine aggregate 
pathology and neurodegeneration have been described in virtually all of the mouse 
models (Bates 2002), indicating its importance to the disease progression. However, there 
is controversy regarding a direct toxic role of polyglutamine aggregates and the  
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Table 6. Mouse models for polyglutamine diseases 
Disease Model design reference 
HD Knock-out 1 (Duyao, Auerbach et al. 1995) 
 Knock-out 2 (Zeitlin, Liu et al. 1995) 
 Transgenic 1, with human HD exon 1 (1-90) 
under human HD promoter (20Q,115Q and 150Q)
(Mangiarini, Sathasivam et al. 
1996) 
 Transgenic 2, with human HD 1-171 under prion 
promoter (18Q, 44Q and 82Q) 
(Schilling, Becher et al. 1999) 
 
 Transgenic 3, with human HD 1-1000 under Rat 
NSE promoter (10Q, 46Q and 102Q) 
(Laforet, Sapp et al. 2001) 
 
 Transgenic 4, with human HD full length cDNA 
under CMV promoter (18Q, 50Q and 91Q) 
(Reddy, Williams et al. 1998) 
 
 Transgenic 5, with yeast artificial chromosome 
(YAC)containing original human full length HD 
gene  (18Q, 46Q and 72Q) 
(Hodgson, Agopyan et al. 1999) 
 
 Transgenic 6, with HD exon 1 under an inducible 
tetO/CMV promoter (94Q) 
(Yamamoto, Lucas et al. 2000) 
 
 Knock-in 1 (72Q and 80Q) (Shelbourne, Killeen et al. 1999) 
 Knock-in 2 (20Q, 50Q, 92Q and 111Q) (Wheeler, White et al. 2000) 
 Knock-in 3 (73Q and 96Q) (Levine, Klapstein et al. 1999) 
 Knock-in 4 (80Q and 150Q) (Lin, Tallaksen-Greene et al. 
2001) 
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Table 6 continued. 
Disease Model design Reference 
SBMA Transgenic 1, with truncated AR under the promoter 
of prion or NFL (112Q) 
(Abel, Walcott et al. 2001) 
 Transgenic 2, with 239Q under human AR promoter (Adachi, Kume et al. 2001) 
DRPLA Transgenic model with full length human atrophin1 
under prion promoter (65Q) 
(Schilling, Wood et al. 1999) 
SCA1 Transgenic 1, with human ataxin1 under PcP2 
promoter (82Q) 
(Burright, Clark et al. 1995)  
 Transgenic 2, modified from transgenic 1 with 
mutated NLS 
(Klement, Skinner et al. 1998)  
 Knock-in with mouse ataxin1 (78Q) (Lorenzetti, Watase et al. 2000) 
SCA2 Transgenic, with human ataxin 2 under pcp2 
promoter (58Q) 
(Huynh, Del Bigio et al. 1999) 
SCA3 Transgenic with truncated human ataxin 3 under 
pcp2 promoter (79Q)  
(Ikeda, Yamaguchi et al. 1996) 
SCA7 Transgenic 1, with human ataxin 7 under pcp2 
promoter (90Q) 
(Yvert, Lindenberg et al. 2000)  
 Transgenic 2, with human ataxin 7 under PDGF-B 
promoter (128Q) 
(Yvert, Lindenberg et al. 2001) 
 
 Transgenic 3, with human ataxin 7 under prion 
promoter (92Q) 
(La Spada, Fu et al. 2001) 
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mechanisms involved in this toxicity (this will be explored further in the mechanism 
section). 
Drosophila and C elegans models (Invertebrate models) 
Drosophila has also been used as a model system for some of the polyglutamine 
diseases, including HD (Jackson, Salecker et al. 1998), SCA1 (Fernandez-Funez, Nino-
Rosales et al. 2000), SCA3 (Warrick, Paulson et al. 1998) and all polyglutamine diseases 
using a pure polyglutamine sequence (Kazemi-Esfarjani and Benzer 2000; Marsh, 
Walker et al. 2000). The disease phenotypes vary from disruptions of the eye retina 
(photoreceptors) to shortening of the life span of the flies. Drosophila models can not 
only contribute to a better understanding of the disease mechanism, but also serve as an 
in vivo screening tool to discover possible modifiers for the toxicity of polyglutamine 
proteins. Indeed, heat shock protein (Fernandez-Funez, Nino-Rosales et al. 2000) and 
histone deacetylase (HDAC) inhibitors (Steffan, Bodai et al. 2001) have been shown to 
rescue the disease phenotype in drosophila models, suggesting that both protein 
misfolding and transcriptional dysregulation are involved in the disease mechanisms. 
Strategies involving up-regulation of the heat shock response and use of HDAC inhibitors 
may lead to therapeutic approaches for polyglutamine diseases. 
Studies using C. elegans as a model system have been carried out using truncated 
huntingtin (Faber, Alter et al. 1999; Parker, Connolly et al. 2001) and GFP tagged 
polyglutamine (Satyal, Schmidt et al. 2000). The abnormal phenotypes were measured by 
a touch response defect (suggesting the neuronal dysfunction), growth retardation and 
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neuronal cell death. The neuronal cell death in the model requires ced-3 (caspase 
homolog) activation, which suggests that cell death is apoptotic (Faber, Alter et al. 1999).  
Cellular models 
 The cellular mechanisms of polyglutamine diseases have been explored by the 
generation and study of a variety of transfected cell models for polyglutamine diseases.  
By transiently/stably overexpressing the full length/truncated huntingtin (Lunkes and 
Mandel 1998; Martindale, Hackam et al. 1998), AR (Butler, Leigh et al. 1998), atrophin-
1 (Igarashi, Koide et al. 1998), ataxin1 (Skinner, Koshy et al. 1997) and ataxin-3 (Ikeda, 
Yamaguchi et al. 1996; Paulson, Perez et al. 1997) in different cell lines, the cell models 
suggest a polyglutamine length dependent toxicity effect. The toxicity requires nuclear 
localization and activation of caspase. Upregulation of heat shock protein can decrease 
the severity of the toxcity (Sittler, Lurz et al. 2001; Waelter, Boeddrich et al. 2001). 
Truncated forms and NLS targeted polyglutamine proteins are much more toxic than full 
length and NES targeted ones (Saudou, Finkbeiner et al. 1998; Perez, Paulson et al. 1999; 
Yasuda, Inoue et al. 1999). The source of cell specificity is obscure, since cell models 
build in a monkey fibroblast cell line (Cos-7 cells) also show similar effects (Skinner, 
Koshy et al. 1997). This may be due to overexpression of polyglutamine proteins in these 
models.  
In vitro models 
In vitro models of interest are studies focused on the biochemical and biophysical 
features of polyglutamine protein, including aggregation kinetics and the structures of the 
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aggregates. These studies include using either recombinant polyglutamine protein 
(Scherzinger, Lurz et al. 1997; Scherzinger, Sittler et al. 1999) or chemically synthesized 
polyglutamine peptides (Berthelier, Hamilton et al. 2001; Chen, Berthelier et al. 2001; 
Chen and Wetzel 2001; Chen, Berthelier et al. 2002; Chen, Ferrone et al. 2002) to carry 
out the protein aggregation in the test tube. By using various techniques of measuring the 
staining features of the aggregates, the aggregation kinetics and the recruitment kinetics 
of polyglutamine aggregates, these studies have revealed that the polyglutamine protein 
can self-assemble into aggregates and this process is a nucleation-dependent 
polymerization (Scherzinger, Sittler et al. 1999; Ross, Poirier et al. 2003). The 
polyglutamine aggregates possess an amyloid-like fibril structure (Chen, Berthelier et al. 
2002). A detailed explanation of the protein aggregation kinetics and the structure of the 
polyglutamine aggregates are illustrated in the molecular and cellular mechanisms section. 
Studies of inhibitors for polyglutamine aggregation or elongation may potentially lead to 
drugs for curing the polyglutamine diseases.  
 
 Molecular and Cellular Mechanisms of polyglutamine diseases  
Polyglutamine sequences  
The glutamine repeat has been found to be the most common amino acid repeat in 
the known protein database (Green 1998).  The functions of the polyglutamine sequences 
in each protein are not clear. A BLAST search (provided by NCBI) of the swissprot 
protein database reveals that about 50% of the polyglutamine containing proteins are 
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transcription factors, or nuclear proteins that may function in gene transcription, and that 
these represent about 2% of the total nuclear protein (data not shown). This suggests that 
the polyglutamine sequence may be involved in gene transcription. Indeed, in vitro 
studies have shown that a polyglutamine sequence can activate gene transcription when 
fused to a DNA binding protein (Gerber, Seipel et al. 1994). It is still not clear how 
polyglutamine protein activates gene transcription - by directly interacting with the DNA 
or by interacting with other transcription factor proteins. Polyglutamine sequences seem 
to be particularly long in the proteins of primates, compared to those of other species. 
The role these sequences may play in evolution is still very obscure (Green 1998). In any 
event, the particularly long polyglutamine sequences in primates and their tendency to 
expand, serve as the basis for the unique problem of CAG repeat expansion that human 
beings must deal with. 
Polyglutamine expansion and protein misfolding   
None of the structures of the 9 disease-related polyglutamine containing proteins, 
either normal or expanded are known. However, the expansion of the polyglutamine 
sequence may result in the protein misfolding. Protein chaperones and the components of 
the ubiquitin-proteasome system have often been found colocalized with polyglutamine 
aggregates in the postmortem brain tissue of polyglutamine diseases, transgenic mice 
models and transfected mammalian cell lines (Cummings, Mancini et al. 1998; Chai, 
Koppenhafer et al. 1999; Waelter, Boeddrich et al. 2001). Protein chaperones usually 
function in assisting protein folding and correcting protein misfolding and the UPS 
system (to be explained in detail later) is the key pathway for degradation of the 
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misfolded proteins if they fail to be corrected by chaperones. The colocalization of these 
components with protein aggregates suggests their involvement in the processing of 
misfolded protein. Moreover, overexpression of chaperone proteins together with the 
expanded polyglutamine proteins has been shown to decrease the aggregation and 
toxicity of polyglutamine proteins in transgenic mice (Cummings, Mancini et al. 1998), 
drosophila (Warrick, Chan et al. 1999) and transfected cell models (Krobitsch and 
Lindquist 2000). In polyglutamine transfected mammalian cell model systems, studies 
using the drug Geldanamycin, which can stimulate the heat shock response in cells and 
therefore induce expression of chaperones, can also decrease mutant huntingtin protein 
aggregation (Sittler, Lurz et al. 2001). This discovery indicates a possible therapeutic 
approach for polyglutamine diseases.  
  Protein misfolding may result in (a) the exposure of the cleavage site and make it 
accessible for protease digestion, which then may process the full length protein into a 
more toxic and highly aggregation-prone fragment containing the expanded 
polyglutamine tract; (b) protein aggregation, which leads to subsequent cellular 
dysfunction and cell death, as further discussed below. 
Cleavage of the full length protein  
 The cleavage of full length mutant protein has been demostrated in HD, SBMA, 
DRPLA, SCA2 and SCA7, but not in SCA1 and SCA3 (Bates 2002), as indicated in 
Table 4. Studies of SCA6 and SCA17 on this aspect have not been reported. Transgenic 
mice expressing the N-terminal fragment of huntingtin generate more severe, earlier 
onset phenotypes compared to knock-in mice (full length mouse huntingtin with an 
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expanded polyglutamine sequence) or mice expressing full length mutant human 
huntingtin. The processing of polyglutamine containing proteins may contribute to 
further pathogenesis of the diseases through three possible mechanisms. First, it may 
facilitate polyglutamine protein interaction and further aggregation by eliminating other 
amino acids that may prevent aggregation. Evidence supporting this comment includes 
the observation that the recombinant glutathione S-transferase (GST) tagged huntingtin 
exon1 protein is soluble in vitro until the cleavage and removal of GST, which then 
results in polyglutamine aggregation (Scherzinger, Lurz et al. 1997).  Second, the cleaved 
fragment containing the expanded polyglutamine sequence is often found relocalized into 
the nucleus (Li, Nakagomi et al. 1998). This may be due to a smaller size that may 
facilitate nuclear entry, or the elimination of a nuclear export signal (NES) that lies in the 
other part of the protein (Schilling, Wood et al. 1999). The NES usually dominates over 
an NLS in determining the cellular location of the protein (Schilling, Wood et al. 1999). 
The translocation of expanded polyglutamine protein into the nucleus appears to be very 
important for the disease pathogenesis as will be explained later in this chapter. Third, 
studies have shown that the expanded polyglutamine protein is cleaved by caspases 3 and 
6 (Wellington, Ellerby et al. 1998; Wellington, Singaraja et al. 2000). The activated 
caspases can then lead to apoptosis and neuronal loss. The initial activity of the caspases 
for cleavage of polyglutamine proteins may be from the low level intrinsic zymogen 
before they are cleaved into the highly active form. Another hypothesis is that the 
expanded polyglutamine containing protein may cause subtle cellular dysfunction before 
being cleaved, which may result in the activation of a small amount of caspase 3 and 6 
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(Wellington and Hayden 2000). This event may be slow at the beginning, but might be 
amplified by the ability of the toxic fragment to generate more caspase activation through 
increased cellular dysfunction, which then cleave even more toxic fragments, and this can 
go into a cycle which amplifies the toxic effect (Wellington and Hayden 2000). The 
caspase inhibitor (z-VAD-fmk) has been shown to increase the lifetime of the HD 
transgenic mice, suggesting a possible therapeutic approach (Ona, Li et al. 1999). 
Polyglutamine aggregation  
 A large amount of data from clinical studies, animal models and invitro models has 
suggested that polyglutamine aggregation is the center for the disease mechanism. But 
how are these aggregates formed? 
 An early hypothesis by Green et al in 1993 suggested that the aggregation of 
polyglutamine proteins might be mediated by transglutaminase (TG) cross-linking (Green 
1993). TG can catalyze the reaction forming a covalent glutamyl-lysine isopeptide bond 
between the two substrates in the presence of calcium (Greenberg, Birckbichler et al. 
1991). This results in the cross-linking of polyglutamine proteins and further facilitates 
their aggregation. This hypothesis was supported by an in vitro study showing that 
expanded polyglutamine containing protein is a good substrate for TG (Kahlem, Terre et 
al. 1996). However, the hypothesis is not supported by evidence from a recent study, in 
which repression of TG expression, by an antisense TG mRNA, failed to decrease the 
aggregation and cytotoxicity of a truncated huntingtin fragment with expanded 
polyglutamine (Chun, Lesort et al. 2001).   
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 Another hypothesis that has been generally accepted, called polar zipper 
formation, was proposed by Max Perutz (Perutz 1996): two antiparallel β-strands of 
polyglutamine repeats can be linked together by hydrogen bonds between the main-chain 
and side-chain amides and undergo polymerization and this will ultimately lead to 
aggregation by polar zipper formation and the formation of amyloid-like aggregates. 
This hypothesis has been greatly supported by the study using bacterial recombinant N-
terminal fragment of huntingtin that can self aggregate into amyloid-like structures in a 
concentration and polyglutamine length dependent manner (Scherzinger, Lurz et al. 1997; 
Scherzinger, Sittler et al. 1999). This suggested that the aggregation of polyglutamine 
proteins is a self-assembly process. 
 Studies on the aggregation kinetics by various labs, including our lab, revealed a 
nucleation dependent fibrillogenesis of polyglutamine peptides, which is similar to the 
Aβ amyloid formation in Alzheimers disease (AD) (Chen, Berthelier et al. 2002; 
Wanker 2002; Ross, Poirier et al. 2003). The first phase of the aggregation kinetics is a 
slow nucleation phase as the polyglutamine protein has to adopt conformational changes 
to form a nucleus. Studies using chemically synthesized peptides (Altschuler, Hud et al. 
1997; Chen, Berthelier et al. 2001) suggest that the monomeric form of polyglutamine 
peptides, both short and long, adopt mainly random coil structure, in contrast to the β-
sheet rich structure of the aggregated from (Chen, Berthelier et al. 2001). A study in our 
lab suggested that the nucleus is a single polyglutamine peptide rather than an oligomeric 
nucleus as is typically visualized for amyloid assembly (Chen, Ferrone et al. 2002). The 
second phase is the fast growth phase when additional polyglutamine monomers 
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associate with the nucleus and form large fibrils. The last phase is when no more net 
growth occurs, which is when the reaction reaches its equilibrium. The critical 
concentration (the lowest concentration before polyglutamine peptides start to aggregate) 
and lag time (the shortest time before the peptides start to aggregate) determine the 
occurrence of the aggregation. In polyglutamine proteins, the longer the polyglutamine 
length, the shorter the lag phase and the lower the critical concentration needed for 
aggregation. This may explain why expanded polyglutamine proteins cause disease, and 
may also explain the correlation between the age-of-onset of the disease and the 
polyglutamine length (Chen, Ferrone et al. 2002). Studies also suggest that the elongation 
of polyglutamine aggregates fits into a docking-locking-blocking model (Berthelier, 
Hamilton et al. 2001), in which a polyglutamine monomer recognizes the binding site of 
a fibril and binds to it (docking; this step is reversible), after which the bound monomer 
undergoes a conformational change (locking; this step is irreversible) and generates a 
new binding site for accepting another monomer. Another monomer then binds to this 
new site and inhibits the dissociation of the previous bound peptide (blocking). 
 Polyglutamine aggregates observed in the NIIs in postmortem HD brain tissue 
(Huang, Faber et al. 1998; McGowan, van Roon-Mom et al. 2000), extracted aggregates 
from transfected cell models (Scherzinger, Lurz et al. 1997; Scherzinger, Sittler et al. 
1999) and the in vitro self-assembly polyglutamine aggregates (Chen, Berthelier et al. 
2002) exhibit some, but not all of the features of a typical amyloid, which made them 
amyloid-like aggregates. These features include the fibrillar ultrastructure that is often 
obtained by EM and Thioflavin T (ThT) binding-dependent fluorescence  (which was 
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used in our lab as an indicator for aggregate formation). Congo red staining and 
exhibiting green birefringence under polarized light (a typical feature for amyloid) has 
been reported. However, only limited number of studies have shown this, most of which 
are just the staining of the polyglutamine aggregates by Congo red. 
 In regards to the toxicity of polyglutamine aggregates, the issue is still under debate. 
Given the fact that NII is a hallmark of the diseases and that the affected brain regions 
correlate well with the formation of the aggregates, aggregates seem to be closely 
associated with the disease. The presence of polyglutamine aggregate pathology in 
virtually all of the transgenic mice models is also supportive of the possible toxicity of 
the polyglutamine aggregates. A cellular study with over-expression of the expanded 
polyglutamine containing proteins results in cell death (Ikeda, Yamaguchi et al. 1996), 
which further supportes a possible toxic role of polyglutamine aggregates. On the other 
hand, a direct toxic role of the polyglutamine aggregates has been questioned and 
aggregates were hypothesized as by-product or even protective for the neurons, 
based on the evidence that (a) the postmortem brain specimen showed NII in healthy 
neurons as well; (b) some HD transgenic mouse models showed NII formation that is not 
associated with cell death (Davies, Turmaine et al. 1997); (c) in a transgenic SCA1 
mouse study, the self association domain (not polyglutamine sequence) of ataxin 1 was 
depleted (Klement, Skinner et al. 1998), which resulted in no visible protein aggregation 
in the mouse, but the mouse still develop neurodegeneration. Also, as the process of 
forming the aggregates from monomer occurs in the cells, there will be monomer, 
intermediate and mature aggregates present in the cells. Which species is/are the toxic 
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species?  The current data using a transfected model cannot directly answer these 
questions and the role of aggregates in cellular toxicity is the subject of the present work.  
 In regards to the current popular topic on the intermediate toxicity in Aβ and other 
aggregated proteins (Bucciantini, Giannoni et al. 2002), there are no reports in the 
literature directly addressing the toxicity of polyglutamine intermediates. In addition, the 
intermediate toxic effect is mainly observed as extracellular toxicity (in Alzheimers 
disease) rather than intracellular (in polyglutamine diseases). 
Nuclear localization and transcription dysregulation  
 Regardless of the original location of the normal polyglutamine containing 
proteins, the aggregated mutant proteins have been found relocated to the nucleus of 
affected neurons, as shown in Table 4. The mechanism of how the aggregates are 
relocated to the nucleus is not clear. It may be mediated through a putative NLS or the 
aggregates may be carried in by interacting with other polyglutamine containing nuclear 
proteins (Bates 2002). But at what stage, monomeric or aggregated, the aggregates get 
into the nucleus, is unknown. Nonetheless, several studies have pointed out that the 
nuclear localization is very important in the disease pathogenesis. When a nuclear 
localization signal (NLS) in the expanded polyglutamine containing protein was mutated 
in an SCA1 transgenic mice model, the mice did not develop neurodegenerative disease 
(Klement, Skinner et al. 1998). Using the exogenous NES on the huntingtin construct, 
which excludes the hutingtin protein from the nucleus, dramatically reduces cellular 
toxicity (Saudou, Finkbeiner et al. 1998; Peters, Nucifora et al. 1999).  
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 The importance of nuclear localization of the polyglutamine aggregates suggested 
that the aggregates may interrupt some nuclear function. And indeed, a large amount of 
studies have suggested dysregulation of gene transcription in polyglutamine expansion 
disease models. DNA microarray studies on gene transcription have revealed an 
abnormal gene transcription pattern in HD transgenic mice (Luthi-Carter, Strand et al. 
2000). The abnormal gene transcription is mainly in the neurotransmitter receptors, 
intracellular signaling mechanisms, retinoic acid receptor machinery and calcium 
homeostasis system (Cha 2000; Luthi-Carter, Strand et al. 2000). CREB-binding protein 
(CBP) (Kazantsev, Preisinger et al. 1999; McCampbell, Taylor et al. 2000; Nucifora, 
Sasaki et al. 2001) and other transcription factors including TBP (Shimohata, Onodera et 
al. 2000) and Sp1 (Perez, Paulson et al. 1998) have been shown to be recruited into 
polyglutamine aggregates and sequestered.  In support of the CBP study, a disease caused 
by loss of CBP is also neurodegenerative (Murata, Kurokawa et al. 2001). Recent studies 
show that histone deacetylase (HDAC) inhibitors rescue the neurodegeneration caused by 
polyglutamine diseases in drosophila (Steffan, Bodai et al. 2001).  The mechanisms by 
which polyglutamine cause the dysregulation of gene transcription may be via 
interactions with transcriptional factors mediated by polyglutamine recruitment 
(recruitment sequestration mechanism) (Ross 2002). 
Ubiquitin proteasome system (UPS) disruption 
 The UPS is an important proteolytic pathway in cells in addition to the lysosome 
and calcium dependent (capain) pathways. It is responsible for up to 90% of short-lived 
protein turnover, and plays an important role in maintaining normal cellular functions 
54 
(Mayer 2000; Vu and Sakamoto 2000). The ubiquitin-proteasome pathway involves two 
steps: the ubiquination step and the proteasome degradation step. First, the small 
ubiquitin protein (76aa) is activated by a ubiquitin activating enzyme (E1), then 
transferred to a ubiquitin-conjugating enzyme (E2) and finally ligated to the protein 
substrate by a specific ubiquitin-protein ligase (E3), leading to the formation of an 
isopeptide bond between the C terminus of ubiquitin (Gly 76) and the side chain of a 
lysine residue on the protein substrate. By repeating this same reaction, a polyubiquitin 
chain can be formed to amplify the signal. Second, the ubiquinated protein is directed to 
the 26S proteasome, which is a multicomponent protease complex made of two 19S caps 
and one 20S core. The protein is then degraded in the proteasome into polypeptides or 
single amino acids (Schwartz and Ciechanover 1999). In polyglutamine disease, a large 
number of components of the UPS, including ubiquitin, some E2, E3 and 20S proteasome 
components, are found to be trapped into the aggregates (Davies, Turmaine et al. 1997; 
DiFiglia, Sapp et al. 1997). These findings indicated that (a) the UPS is involved in 
degradation of the misfolded protein containing the expanded polyglutamine tracts and (b) 
the UPS fails to degrade at least some expanded polyglutamine proteins, instead 
becoming trapped into protein aggregates, resulting in loss of normal UPS function. This 
may in turn result in abnormal accumulation of other proteins destined for degradation, 
which further results in cell dysfunction and cell death (Bence, Sampat et al. 2001). 
Treating cells with a proteasome inhibitor, lactacystin, can lead to an increased 
polyglutamine aggregation and toxicity in a transfected cell model (Cummings, Reinstein 
et al. 1999). This further supports the importance of the UPS in polyglutamine diseases. 
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Neuronal cell death 
 Undoubtedly, the dramatic brain atrophy observed in postmortem brain tissue 
results from severe neuronal cell death occurring in the late stages of polyglutamine 
disease (DiFiglia, Sapp et al. 1997). This was further confirmed by various animal and 
cellular model studies (Evert, Wullner et al. 2000). But the mechanism of the cell death 
remains to be determined. 
Cell death mechanisms are divided into two based categories, apoptosis and 
necrosis, by their distinct features (Kerr, Wyllie et al. 1972). Apoptosis refers to an 
inherently programmed phenomenon and necrosis refers to a violent and rapid 
disruption of major cell functions. The detailed key features of apoptosis and necrosis are 
summarized and compared in Table 7. However, recent studies suggest that there are 
other cell death mechanisms that contain some of the key features of either or both these 
two types of cell death, but which cannot fit exactly into either of the categories (Bursch, 
Ellinger et al. 2000). A broader grouping of cell death mechanisms separates cell death 
into two classes:  programmed or non-programmed cell death.  Programmed cell death 
(PCD) is defined as requiring new gene activation and protein synthesis to mediate cell 
suicide. This class of cell death includes, in addition to apoptosis, autophagic PCD (a 
unique cell death type induced by certain DNA damage, that requires gene transcription, 
but dose not follow the caspase cascade, and instead proceeds through autophagic 
vacuoles formation and self-destructure (Bursch, Ellinger et al. 2000)), paraptosis (a 
newly proposed cell death type that also requires new protein synthesis, but presents a 
necrotic-like morphologic change (Sperandio, de Belle et al. 2000)) and perhaps others  
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Table 7. Summary and comparison of apoptosis and necrosis 
Features Apoptosis Necrosis 
Inducers Developmental/Programmed 
Degenerative changes 
Growth factor depletion 
Mild ischemia, radiation, etc. 
 
Severe and sudden injury, 
physical or chemical trauma 
(toxic, massive ischemia and 
high dose radiation, etc.) 
Cellular 
consequences 
1st phase: chromatin condensation; cell 
shrinkage (expose of phosphatidylserine  
on the membrane is a very early 
phenomenon) 
 
2nd phase: fragmentation of both nucleus 
and cytoplasm and form apoptotic body 
 
3rd phase: degradation of residual nuclear 
and cytoplasmic structures in phagosome, 
very little or no inflammation. 
 
1: Cytoplasmic swelling 
 
2: Rapid plasma membrane 
rupture  
 
3: Organelles breakdown with 
remarkably little nuclear change  
 
4: Nuclear swelling and break-
down and development of 
massive inflammation.   
 
 
Nuclear 
changes 
1: Chromatin condensation and large 
fragmentation 
 
2: DNA laddering: 180-200bp DNA 
fragmentation 
 
1: Plumping and lysis of 
nucleus.  
 
2: Diffuse and random DNA 
degradation 
Cytoplsmic 
changes 
1: Alterations of cytoskeleton resulting in 
rapid budding and blebbing of the plasma 
membrane.  
 
2: Involution and contraction of cell 
organelles (Mitochondria may release 
cyto c, but not very obvious swelling, 
still maintain the contact structure.) 
 
3: Cells lose contact with other cells and 
round up or float in the medium in cell 
culture.  
 
1: ER swelling, vesiculation and 
rupture of membranes  
 
2: Mitochondria: swelling and 
lose cristae, misshappen and 
rupture and lose 
intramitochondrial granules. 
 
3: Lysosome: swells and rupture 
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yet to be defined. Non-programmed cell death is often used synonymously with necrosis, 
since its definition is broad enough to cover all the features described for a non-
programmed cell death.  In the following paragraph, I will focus mainly on apoptosis 
mechanistic pathways. 
Studies on apoptosis signal pathways suggest that apoptosis mainly involves two 
pathways, which are dependent on the stimuli or inducers: a death receptor pathway and a 
mitochondrial pathway (Strasser, O'Connor et al. 2000).  
The death receptor pathway can be induced by a variety of extra cellular stimuli, 
including cytokines like TNFα (tumor necrosis factor α) and Fas-L (Fas ligand). These 
death ligands can bind to the death receptor TNFR-1 and Fas/CD95/Apo-1 and cause 
trimerization and activation of the receptor. The activation of the receptors results in a 
conformational change and exposure of the intracellular death domain (DD), which then 
recruits a DD-containing adaptor protein such as FADD (Fas associated death domain 
protein). FADD then undergoes oligomerization, exposing its DED domain (death 
effector domain), which in turn recruits DED domain-containing initiator procaspases (8, 
10). Procaspase 8 and 10 also undergo oligomerization and then auto-cleave or inter-
cleave between each other to generate activated forms of caspases. Caspase 8 and 10 can 
directly cleave and activate effector caspases (3, 6, 7) (Earnshaw, Martins et al. 1999), 
which then cleave their substrates, leading to the apoptosis phenomenon: (a) cleavage of 
cytoskeleton proteins like actin, gelsolin, etc., resulting in cytosleleton rearrangement and 
membrane blebbing; (b) cleavage of nuclear structural proteins like lamin, nuclear matrix 
protein, etc., resulting in nuclear shape changes; (c) generation of the 180-200bp 
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internucleosomal DNA fragments, which is a characteristic feature detected on agarose 
gel, called the DNA ladder. This ladder results from cleavage of DFF (DNA 
fragmentation factor) 45/40, and release of DFF 40 which can oligomerize into large 
Dnase, cleaving double stranded DNA at internucleosome positions; (d) among the 
caspase substrates, Poly (ADP-ribose) polymerase (PARP) can be cleaved to an 85kD 
fragment, and this has been used as a method to detect apoptosis.  
The mitochondrial pathway (Desagher and Martinou 2000) is usually death receptor 
independent and intracellularly induced. For example, growth factor withdrawal and 
DNA damage can activate the mitochondrial pathway for apoptosis, which is mediated 
through the proapoptotic BCL-2 family, proteins that can disrupt mitochondrial integrity 
and induce release of cytochrome c. On its release cytochrome c (a 13 kD electron 
transfer protein) binds to adaptor protein Apaf-1 in an ATP/dATP dependent manner and 
causes oligomerization of Apaf-1, which in turn recruits procaspase 9. On the recruitment 
to Apaf-1, procaspase 9 also undergoes oligomerization, which leads to its cleavage to an 
active caspase 9. Caspase 9 can further recruit and activate downstream effector caspases 
3, 6, 7, and result in activating of apoptosis cascade (Earnshaw, Martins et al. 1999). The 
apoptosis pathway is illustrated in Figure 5. 
 As for polyglutamine diseases, although thzxe exact pathway for cell death is not 
completely understood, there is evidence suggesting an apoptotic cell death mechanism.  
DNA fragmentation has been detected by TUNEL staining in both HD brain (Dragunow, 
Faull et al. 1995) and a mouse model (Reddy, Williams et al. 1998). Caspase activation 
has been detected (Sanchez, Xu et al. 1999), and inhibition of caspase activation by Z- 
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Figure 5. General cell signaling pathways for apoptosis  
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VAD-FMK can increase cell survival (Kim, Lee et al. 1999) (Ona, Li et al. 1999). On the 
other hand, the presence of gliosis in the affected brain in some polyglutamine diseases 
suggests the involvement of necrosis. Nonetheless, the bulk of the data gathered so far 
suggests a nonclassic apoptosis pathway for polyglutamine disease (Gutekunst, Norflus et 
al. 2002). 
Neuropil aggregates and  neuron projection failure 
 There is an emerging hypothesis on the mechanism of the polyglutamine diseases, 
especially on HD, which suggests that the dysfunction of neuronal synaptic transportation, 
due to its physical blockage by aggregates in the dendrites, or due to the degeneration of 
the dendrites induced by the toxic effect of the aggregates, may be responsible for the 
death of projected neurons due to lack of support (Sapp, Penney et al. 1999). In HD, this 
hypothesis was supported by the finding of the accumulation of the aggregates in the 
dendrites of corticostriatal projection neurons (Gutekunst, Norflus et al. 2002), which 
may be responsible for neuronal death of the striatal neurons. In another study on the 
ataxin-7 transgenic mouse model, in which the expression of ataxin-7 was controlled by a 
specific promoter that restricts the expression of ataxin-7 to certain designated neurons,  
neuronal degeneration occurs postsynaptic to the neurons expressing ataxin-7 and 
containing ataxin7 aggregates (Yvert, Lindenberg et al. 2000), suggesting a neuronal 
projection failure mechanism. 
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Cell specificity 
 Despite the wide expression of polyglutamine proteins in a variety of tissues in 
the body, and their diverse functions, only neurons appear to be victimized by 
polyglutamine expansion disease. The source of this cell type specificity remains 
unknown. Possible hypothesis have been made that if the polyglutamine aggregation is 
the basis for the disease mechanism, the critical concentration for aggregation (Chen, 
Ferrone et al. 2002) can only be reached in the cells that are long lasting, such as neurons 
(Ferro, dell'Eva et al. 2001).  
As for the neuronal specificity observed in each polyglutamine diseases, there are 
a number of possible explanations. (1) The expression levels of the polyglutamine 
proteins for different cell types may be different for each disease, which would be 
expected to result in the protein aggregation kinetics also being different, since the 
aggregation process is concentration-dependent (Kosinski, Cha et al. 1997); (2) Differing 
functions of the different disease proteins, and /or differing profiles of interacting 
proteins (e.g., in a recruitment mechanism) for each disease proteins, may also account 
for the specificity in each disease; (3) The protease that processes the expanded 
polyglutamine proteins, the chaperones that protect the proteins against misfolding, and 
the ubiquitin-proteasome system that facilitates the degradation of incorrect proteins may 
vary in different neurons, which could likewise result in different responses to 
polyglutamine expansion and aggregation in different neurons; (4) The domain structure 
of different polyglutamine containing proteins have no relationship to each other except 
for the polyglutamine sequence itself; these unshared domains may specify each disease 
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with its special features, as an overlay above the shared polyglutamine aggregation 
driving forces of the pathology. In support of this, fragmented polyglutamine disease 
proteins seem to cause a more widespread neurodegenerative disease, with loss of 
regional specificity (Bates 2002). 
 
 The possible cell death mechanisms are illustrated in Figure 6. 
63 
 
 
Figure 6. Summary on the hypothesis of the cellular mechanism of polyglutamine 
disease. Modified from (Ross, Wood et al. 1999) 
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 CHAPTER 2  
INTRODUCTION AND RATIONALE TO PRESENT WORK 
 
In the polyglutamine diseases, evidence drawn from extensive studies has led to 
theories on the molecular and cellular mechanism of the disease that focus on a long 
polyglutamine sequence in the respective proteins，as encoded by an expanded CAG 
repeat in the open reading frame of the affected genes (reviewed in chapter1). But how 
these expanded polyglutamine sequences are toxic to neurons is not clear. A number of 
model systems based on expression of the mutant gene have been generated in order to 
understand the mechanisms of the disease and to discover a possible cure. However, there 
are still questions that cannot be directly answered by these model systems, and 
ambiguities that cannot be explained by these studies. Among these are: a direct toxic 
role of the disease pathologic hallmark, normally, the polyglutamine aggregates, is still 
not universally accepted; the sub-cellular location where aggregate toxicity is expressed 
is also open to debate; and the mechanism by which aggregates induce neuronal death is 
still a mystery. Technical factors limit the ability of many studies to conclusively test the 
role of polyglutamine aggregates in triggering disease pathology.  Cell and animal 
models require over-expression of soluble, monomeric polyglutamine forms as necessary 
precursors to aggregate formation, making it difficult to draw conclusions about the 
relative toxicities of native monomer, misfolded monomer, aggregation intermediates, or 
some form of mature aggregate.  It is also difficult to detect and quantify the small 
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aggregates that may be the most potent toxic forms of polyglutamine (Chen, Berthelier et 
al. 2001). 
 In this laboratory, biochemical studies directly focused on the polyglutamine 
peptides have uncovered some important and fundamental features of polyglutamine 
peptides: first, a comprehensive protocol of solubilizing and disaggregating 
polyglutamine peptides make it possible to conduct aggregation studies in vitro (Chen 
and Wetzel 2001); second, studies on polyglutamine aggregation behavior in vitro, 
including the development of a microtiter plate assay for polyglutamine aggregate 
elongation (Berthelier, Hamilton et al. 2001), suggest a recruitment mechanism of 
cytotoxicity (Chen, Berthelier et al. 2001); third, detailed studies characterizing the 
amyloid-like features of polyglutamine aggregates and their assembly kinetics (Chen, 
Berthelier et al. 2002), including indications that the age-of-onset of these diseases is 
linked to polyglutamine aggregation nucleation (Chen, Ferrone et al. 2002). These 
discoveries put us in a position of developing a new cell model system and to thereby 
study the cellular mechanisms of polyglutamine diseases from a different direction, 
which could overcome the technical barriers of the existed model systems. For the first 
time, we directly introduced polyglutamine aggregates prepared in vitro from simple 
polyglutamine peptides into the cytoplasm or nucleoplasm of cells in culture to study the 
effects on the cells. 
Chapter 3 describes our efforts to overcome the challenge of getting polyglutamine 
aggregates into mammalian cells. Chapter 4 describes the results of comprehensive 
cytotoxicity studies, in which aggregates are directed to either the cytoplasm or 
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nucleoplasm. Chapter 5 describes the extension of this cytotoxicity study to include the 
effects of soluble polyglutamine peptides in this system. Chapter 6 describes further 
studies to better understand the cell death mechanism observed in our model system. 
Chapter 7 describes the use of our cell model to evaluate the ability of a recently 
discovered (A. Thakur and R. Wetzel, unpublished) polyglutamine elongation inhibitor to 
inhibit polyglutamine cytotoxicity. Chapter 8 consists of a general conclusion, and 
chapter 9 contains a detailed material and experimental methods section.  
Part of the work described in Chapter 3, 4 and 5 has been published in a paper 
entitled Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian 
cells, with co-authors John R. Dunlap, Richard B. Andrews and Ronald Wetzel, in 
Human Molecular Genetics 11(23): 2905-17, 2002. 
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CHAPTER 3  
OVERCOMING THE CHALLENGE OF GETTING 
AGGREGATES INTO CELLS 
 
The properties of in vitro-grown aggregates 
The properties of the peptides used in the experiments 
 All of the aggregates used in this work were made from controlled in vitro 
aggregation of chemically synthesized peptides. Chen and Wetzel (Chen and Wetzel 
2001) demonstrated a method to solublize chemically synthesized polyglutamine peptides, 
including those in the pathological length range, by using a combination of the organic 
solvents TFA and HFIP (described in chapter 9). The aggregation of these monomeric 
peptides was carried out in the test tubes under controlled conditions to generate 
polyglutamine aggregates that resemble the features of polyglutamine aggregates 
produced in vivo (Chen and Wetzel 2001). Table 8 lists the sequences of all of the 
peptides used in this study.  Peptides were routinely labeled at the N-terminus with 
fluorescein to provide a means to track the aggregates by microscopy and flow cytometry.  
Some peptides were also synthesized to include an N-terminal nuclear localization signal 
(NLS) (Kalderon and Smith 1984) or nuclear export sequence (NES) (Mowen and David 
2000).  We worked with two types of polyglutamine sequences, one (Q20) shorter than the  
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Table 8. Synthetic peptides used in the experiments 
Peptide Name                                 Peptide Sequence MW, 
Daltons 
F-Q42 Nα-Fluor-KKQ42KKCOOH   
 6,656 
F-NLS-Q42 Nα-Fluor-PKKKRKVGG-Q42KKCOOH  7,378 
F-NES-
Q42 
Nα-Fluor-LPPLERLTLDGG-Q42KKCOOH    7,662 
F-Q20 Nα-Fluor-KKQ20KKCOOH  3,452 
F-NLS-Q20 Nα-Fluor-PKKKRKVGG-Q20KKCOOH  4,175 
F-NLS-CspB-1 Nα-Fluor-PKKKRKVGG-
MLEGKVKWFNSEKGFGFIEVEGKKCOOH 
 4,127 
PGQ9(P2,3) Nα-KKQ9PGQ4PQ4PGQ4PQ4PGQ9KKCOOH    5,544 
aIn the Table, F and Fluor is a fluorescein group, as shown below. 
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pathological cutoff of 36 glutamines, and one (Q42) longer.  Both peptides include 
flanking pairs of lysine residues to improve the initial solubility of these peptides 
(Altschuler, Hud et al. 1997) and allow slower, more ordered, in vitro aggregation (Chen 
and Wetzel 2001).  For a control peptide, we chose the cold shock protein fragment Csp-
B1, which has been shown to form amyloid-like aggregates in solution (Gross, Wilkins et 
al. 1999).  The peptide PGQ9(P2,3) listed in Table 8 is an elongation inhibitor  discovered 
in our laboratory (A. Thakur and R. Wetzel, unpublished) which will be discussed in 
detail in chapter 7.  
The features of the aggregates made in vitro 
 Studies (Chen, Berthelier et al. 2001; Chen, Berthelier et al. 2002) have shown that 
polyglutamine aggregates generated in our laboratory possess amyloid-like features, 
including (1) a high content of β-sheet measured by circular dichroism (CD) spectroscopy; 
(2) binding to the dye thioflavin-T and altering of its fluorescence properties; (3) binding 
of Congo red; (4) fibrilar ultrastructures observed by electron microscopy (EM). Csp-B1 
aggregates have also been shown previously to exhibit amyloid-like properties (Gross, 
Wilkins et al. 1999).  Figure 7 shows EMs of the aggregates used in this study. All the 
peptides form ordered aggregates of approximately the same width.  However, the 
polyglutamine aggregates are short and curvilinear, while the CspB-1 aggregates are 
relatively long and straight.   
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Figure 7.  Ultrastructure of in vitro aggregates.  Aggregates were fixed to mica grids 
and negatively stained with 0.25% w/v potassium phosphotungstate solution.  
Micrographs were collected on a Hitachi H600 scanning electron microscope.  Shown are 
aggregates of (A) F-NLS-Q42; (B) F -Q42 (sonicated); (C) F-NLS-Q20; (D) F-Q20; (E) 
F-NES-Q42; (F) F-NLS-CspB-1. 
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The stability of the aggregates 
 These aggregates are stable in vitro. Using HPLC to monitor the dissociation of 
the monomeric peptides (which has the capacity of detecting 2% dissociation), we found 
that neither Q20 nor Q42 aggregates dissociate measurably after up to five days incubation 
at 37 °C in PBS (Figure 8).  After five days, the Q20 aggregates begin to dissociate 
slightly, while Q42 aggregates show no measurable dissociation; this is consistent with 
their relative critical concentrations in aggregation (Chen, Berthelier et al. 2001). Csp-B1 
aggregates dissociated slightly (5%) after incubation for 3 days under these conditions.   
These polyglutamine peptide aggregates also resemble in vivo disease protein 
aggregates in their stability to SDS treatment. Figure 9 shows a Coomassie Brilliant Blue-
stained gel with individual lanes loaded with either aggregates or monomers of the Q20 
and Q42 peptides, after 3 minutes in boiling SDS gel loading buffer. The gel shows that 
no detectable peptide is released from a Q42 aggregate and only a small amount (＜10%) 
of peptide is released from a Q20 aggregate, suggesting that these aggregates are highly 
resistant to dissolution in boiling aqueous SDS.  In the experiment, all of the samples 
were loaded at the same amount (5ug), however, the aggregates that could not enter into 
gel remained in the loading well, and were washed out when opening the gel cassette, 
with very little still visible at the top of the stacking gel.  Although the peptide migration 
rate in the gel is not as expected for peptides of their molecular weights, as indicated by 
the standard molecular weight markers, this is probably due to an anomaly in the 
electrophoretic properties of polyglutamine sequences.  
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Figure 8.  In vitro stability of aggregates by monomer dissociation detection in the 
solution.  Different preparations of aggregates were incubated in PBS at a concentration 
of 10 uM (monomer equivalents) at 37 °C and aliquots were processed as described in 
Materials and Methods to measure aggregate dissociation.  The ordinate shows the 
percentage of total aggregate-associated peptide released into the supernatant at various 
incubation times. Open squares, F-NLS-Q42; open diamonds, F -Q42; open circles, F-
NLS-Q20; open triangles, F-Q20; filled squares, F-NLS-CspB-1.  
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Figure 9. SDS gel for the polyglutamine aggregates and monomers.  In vitro prepared 
polyglutamine aggregates (left) and monomers (right) were boiled in 2% SDS loading 
buffer for 3 min. and then subject to electrophoresis. Monomers were used as control to 
indicate the dissociation of the aggregates.  
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Introduction of aggregates into mammalian cells 
Mammalian cells used in the study 
We attempted to introduce these aggregates into mammalian cells. We chose to 
use both PC-12 cells and Cos-7 cells in our experiments. The PC-12 cell line was 
established from a rat adrendal gland pheochromocytoma (Greene and Tischler 1976). 
Induced by nerve growth factor (NGF), PC-12 cells can differentiate into a neuronal 
phenotype with extended long, branching neuronal-like processes. PC-12 cells, with or 
without NGF induction, can synthesize and store the catecholamine neurotransmitters 
dopamine and norepinephrine, and hence have been widely used as a model system for 
neurobiological studies including Huntingtons disease research (Li, Cheng et al. 1999).  
The Cos-7 cell line is a transformed monkey kidney fibroblast cell line (Gluzman 1981). 
The idea of including both PC-12 and Cos-7 cells in the experiments is to see whether or 
not there is a difference between neuronal and non-neuronal cells in response to the 
aggregate treatment. 
Delivering the aggregates into cells by a liposome-mediated method 
We first used a liposome-mediated method to introduce aggregates into cells.  The 
idea is that liposomes can encapsulate small polyglutamine aggregates in PBS solution 
upon hydration, and then fuse with the hydrophobic cell membrane, delivering the 
aggregates into the cytoplasm. Flow cytometry studies (Figure 10) showed that it is 
possible to efficiently deliver aggregates of fluoroscein-tagged Q42 polyglutamine  
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Figure 10.  Introduction of aggregates into cells by the liposome mediated method.  
PC-12 cells (top series) or Cos-7 cells (bottom series) were treated with (right) or without 
(left) liposomes encapsulated F-Q42 aggregates for 4 hours, which were then washed out 
and substituted with fresh medium for another 20 hours (right).  The cells were collected 
and analyzed by flow cytometry. The M1 region of each recording represents background 
fluorescence, the M2 and M3 regions are from fluoroscein fluorescence.    
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 (-) control     
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aggregates into both PC-12 and Cos-7 cells by this liposome-mediated method.  With 
both cell types, a four-hour incubation with packaged polyglutamine aggregates results in 
80% or more of the cells exhibiting fluoroscein fluorescence. 
Aggregates also get into cells by direct incubation method 
 We also included a control experiment for the liposome-mediated method by 
directly incubating aggregates with cells without liposome packaging. Surprisingly, this 
control also led to a high percentage of fluorescent cells.  Figure 11 shows that although 
aggregates mixed directly with cells are taken up more slowly, after 24-48 hours 80% or 
more of cells mixed with aggregates become fluorescent.  We decided to conduct further 
experiments without liposome packaging, in order to reduce the possibility of artifacts 
associated with added lipids in the cell toxicity studies. 
 
Localization of the aggregates in the cells 
Confocal microscopy confirms the aggregates are inside the cells 
 In order to confirm that aggregates were internalized within cells and not simply 
adhered to the outer cell surface, we used fluorescence confocal microscopy.  It scans 
individual focal planes of a cell, which very accurately tells whether the aggregates are 
inside a cell or not. Figure 12 shows micrographs of interior focal planes of both PC-12 
and Cos-7 cells that had been incubated with F-Q42 aggregates for 24 hours.  Figure 12  
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Figure 11.  Aggregates getting into cells by direct incubation method.   Sonicated F-
Q42 aggregates were mixed with PC-12 cells (top series) or Cos-7 cells (bottom series) at 
various times analyzed by flow cytometry.  The M1 region of each recording represents 
background fluorescence, the M2 and M3 regions are from fluoroscein fluorescence. 
48hrs.       
M2+M3=81.54% 
4hrs.      
M2+M3=30.08% 
24hrs.     
M2+M3=67.19% 
 48hrs.     
M2+M3=86.37% 
4hrs.     
M2+M3=69.81% 
24hrs.   
M2+M3=84.67%
Cos-7 cells 
PC-12 cells 
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Figure 12.  Confocal microscopy of aggregate-treated cells.  PC-12 cells (upper) and 
Cos-7 cells (lower) were treated 24 hours with F-Q42 aggregates. Left pictures shows that 
the aggregates were associated with the cells at a lower magnification. Right pictures 
clearly show that the aggregates are inside the cells at higher magnification. 
 
PC-12 cells 
Cos-7 cells
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clearly shows that these aggregates are located within cells, rather than adherent to the 
outside of the cells.   
Nuclear localization of the aggregates mediated by NLS 
 In order to probe the dependence of aggregate toxicity on sub-cellular localization, 
we attempted to deliver them into the nuclei of cells.  To do this, we added to some 
synthetic peptides a sequence consisting of the NLS sequence PKKKRKV (derived from 
SV40 (Boulikas 1993)) with a fluorescein-tag on the N-terminus and a Gly-Gly spacer on 
the C-terminus (Table 8).  Flow cytometry shows that aggregates of such peptides are 
taken up into cells about as efficiently as are aggregates without the NLS, as seen in 
Figure 14-16 in Chapter 4.  When the nuclei of these cells are isolated and analyzed by 
confocal microscopy, fluorescent foci are clearly observed within the nuclear envelope 
(Figure 13).  In contrast, aggregates of F-Q42 lacking an NLS accumulate on the nuclear 
membrane, but do not penetrate into the nucleus (Figure 13). 
Sonication and filtration optimized the efficiency by which aggregates are 
taken up into cell nuclei 
 To improve the efficiency of cellular and nuclear uptake, we devised methods to 
produce a smaller effective particle size through sonication and membrane filtration 
(Chapter 9, Materials and Methods).  Figure 13 shows that aggregates of F-NLS-Q42 
become more efficient at crossing into the cell nucleus as the average particle size of the 
aggregates gets smaller.  Decreasing the particle size of F-Q42 aggregates, in contrast, 
does not alter their fundamental inability to penetrate the nucleus.  Based on their  
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Figure 13. Nuclear localization of the aggregates.  Confocal microscopy shows the 
nuclei extracted from PC12 cells incubated 24 hrs with various aggregates. The upper 
series show that F-Q42 aggregates do not penetrate beyond the nuclear membrane.  The 
middle series show that aggregates of F-NLS-Q42 peptides penetrate into the nucleus, 
with increased efficiency as their size decreases.  The lower panel shows that F-NLS-
CspB-1 aggregates, sonicated and subjected to a single filtration through a 1.2 um filter, 
very efficiently penetrate the nucleus. 
no filtration 1.2um filtered 0.45um filtered 0.2um filtered
F-NLS-Q42 
no filtration 1.2um filtered 0.45um filtered 0.2um filtered
F-Q42 
1.2um filtered  
F-NLS-CspB-1
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filtration behavior, aggregates prepared in this way appear to have an average effective 
size of greater than 100 nm, while the functional diameter of the nuclear pore is normally 
considered to be no larger than about 26 nm (Talcott and Moore 1999). Nonetheless, the 
dependence of aggregate uptake into the nucleus on the presence of an NLS strongly 
suggests that it occurs via the NLS-associated nuclear pore.  Figure 13 also shows that 
fluoroscein tagged NLS-CspB-1 aggregates are very efficient at getting into the nucleus.  
This shows that aggregate transport across the outer and nuclear membranes does not 
depend on the polyglutamine sequence. 
Discussion 
Do in vitro aggregates possess the critical features of in vivo aggregates? 
 Although conditions in the cell are very different from those in a test tube, the 
aggregates made in vitro may in their critical features resemble aggregates produced in 
vivo. First, the aggregates found in vivo made up of the mutant protein containing an 
expanded polyglutamine sequence, and the soluble polyglutamine peptides we generate 
in our studies, are both chemically and conformationally similar to each other (Chen and 
Wetzel 2001; Bennett, Huey-Tubman et al. 2002). Second, it has been generally accepted 
that the process of aggregate formation is mediated through a self-assembly of 
polyglutamine containing proteins into aggregates (Wanker 2002; Ross, Poirier et al. 
2003). Similarly, studies of the aggregation kinetics of the peptides used in our study 
reveals a nucleation-dependent polymerization that may be the fundamental mechanism 
of polyglutamine aggregation (Chen, Berthelier et al. 2002; Chen, Ferrone et al. 2002). 
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Third, the aggregates that we generate in vitro present amyloid-like features (Chen, 
Berthelier et al. 2002), which are also similar to those generated in vivo by 
polyglutamine-containing protein, at least according to some reports (Davies, Turmaine 
et al. 1997). Fourth, aggregates of ataxin 3 (Chen, Berthelier et al. 2002), as well as 
aggregates isolated from HD brain tissue (Berthelier, unpublished), have the ability, in 
analogy to synthetic polyglutamine aggregates to serve as a matrix for polyglutamine 
elongation. Taken together, the similarity of the aggregates we make in vitro to the 
aggregates generated in cells supports the relevance of our aggregate toxicity.  
How are the in vitro produced protein aggregates taken up by cells and 
cell nuclei? 
 It is of great interest how the protein aggregates described above, despite their large 
sizes, are so efficiently taken up by cells and delivered into cell nuclei.  This surprising 
result is not restricted to polyglutamine sequences, since we observed similar or greater 
nuclear uptake of Csp-B1 aggregates.  All of the aggregates described here exhibit 
amyloid-like structures in the EM and carry a net positive charge at neutral pH; it is 
possible that one or both of these features may contribute to their efficient membrane 
transport.  Since multiple localization signals are thought to facilitate passage of large 
substrates through the pore (Talcott and Moore 1999), the fact that fibrils made of NLS-
tagged peptides consequently contain significant numbers of NLS, explain the ability of 
these aggregates to gain passage through the nuclear pore.  Our results do suggest that 
even relatively large aggregates of polyglutamine and other sequences can be transported 
across the nuclear membrane in a process mediated by an NLS.  This suggests that it is 
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possible that in the disease mechanism polyglutamine aggregates containing crytic NLS 
sequences [or co-aggregates between disease proteins and other polyglutamine proteins 
that contain NLS sequences (Preisinger, Jordan et al. 1999)] might form in the cytoplasm 
and then be transported into the nucleus.  
 It is formally possible that aggregate dissociation to monomers, followed by 
reaggregation, might contribute to cell or nuclear uptake of the aggregates. However, the 
results from in vitro aggregate stability studies suggested that the aggregates are very 
stable for the times and conditions of the treatment (Figure 8). It is very unlikely that the 
observed ability of these aggregates to be transported across cell and nuclear membranes 
is due to a disassembly-reassembly pathway; this is especially true for the F-NLS-Q20 
aggregates, since Q20 peptides would require high concentrations and long incubation 
times to re-aggregate (Chen, Berthelier et al. 2001). If Q20 aggregates had disassociated 
during incubation with the cells, it would be impossible for them to re-aggregate under 
these conditions. 
The problems and limitations in getting the aggregates into cells 
 Although aggregates can be delivered into cells by the direct incubation method, 
there are some problems associated with it. First, theres no control over how much 
aggregate gets into cells and nuclei. So it is possible that some cells take up more 
aggregates than others, leading to different responses. Thus, in response to the same 
treatment, one may see a wide range of responses among the cells, from cells with severe 
effects (due to high concentration of aggregates inside the cells or nuclei) to cells with 
little or no effects (because there are little or no aggregates inside the cells or nuclei). 
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Second, there is no way to synchronize the uptake of aggregates by all the cells. We 
know that it takes about 24-48 hours for 80% of cells to acquire the aggregates. But there 
may be cells that take up aggregates in only 4 hours and quickly exhibit effects, while at 
this time other cells may be without aggregates and without effects. Thus the time course 
of the effects we observed reflects the system as a whole. Third, we have observed that in 
the experiments, there are a large amount of big aggregates attached to the membrane of 
the cells, presumably because the aggregates, which carry a net positive charge, are 
attracted to the negatively charged cell membrane.  Sonication and filtration to decrease 
the size of the aggregates seems to help to reduce this effect. But, despite this, the 
aggregates tend to re-associate together into large clusters again, after filtration, during 
incubation with the cells. This effect is especially strong in higher concentration 
treatments. These large aggregates are not delivered into the cells, but give false signals 
for cells containing aggregates in the flow cytometry determination and also made it 
impossible to measure how much aggregate is in the cells by flow cytometry or by 
fluorescence detection methods. 
 One way to improve these experiments would be to control delivering of aggregates 
to the cells. One could, for example, use microinjection to directly inject aggregates into 
cells in the future. Another improvement would be to devise a way to measure aggregate 
uptake directly on a cell-by-cell basis. For example, one might use cells transfected with 
construct for low level of expression of a huntingtin (htt) [with moderate length of 
polyglutamine (~30) that does not aggregate rapidly] fusion to a fluorescent protein 
(other than green) for treatment with fluorescein-tagged polyglutamine aggregates. If the 
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expressed peptide is recruited to the aggregates, it would cause FRET (fluorescence 
resonance energy transfer), which can be measured. The amount of FRET experienced by 
the expressed protein could be related to the amount of aggregates taken up; this could be 
done on a cell-by-cell basis using flow cytometry. 
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CHAPTER 4 
TOXICITY OF AGGREGATES INTRODUCED INTO THE 
CYTOPLASM AND NUCLEOPLASM 
 
Initial studies on cytotoxicity of the aggregates using flow cytometry 
Toxicity of cytoplasmic aggregates 
From the confocal microscopy study, we observed that the majority of the 
aggregates of the F-Q45 peptide lacking an NLS are located in the cytoplasm. We then 
further studied the effect of these aggregates on cell viability. We used propidium iodide 
(PI) exclusion, a standard staining method for distinguishing viable from non-viable cells. 
If PI is able to penetrate to the nucleus due to damage to cell membranes, it intercalates 
into nucleic acid and by doing so (a) concentrates in the nucleus and (b) exhibits 
enhanced fluorescence (Slezak and Horan 1989) detectable in flow cytometry and 
confocal microscopy.  Figure 14 shows that PC-12 cells efficiently take up F-Q42 
aggregates but remain viable, despite their aggregate burden, with only 12% of the cells 
(essentially identical to the control 11%) exhibiting PI staining.  The results are the same 
for Cos-7 cells, with 12% of cells dying in the presence of cytoplasmic aggregates, 
essentially identical to the control value of 10% cell death without aggregates. This data  
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Figure 14. Flow cytometry on cell viability of cytoplasmic aggregates. PC-12 cells 
(top series) or Cos-7 cells (bottom series) were incubated with (right) or without (left) F-
Q42 aggregates for 24 hrs, then stained with propidium iodide and analyzed by flow 
cytometry.  The individual panels show the result of one experiment each in which 1.2 
um filtered aggregates were mixed with cells and evaluated for both cell uptake of 
aggregates (FL-1) and cell death (FL-3).  Panel labels reflect percent cell death by PI 
staining.   
F-Q42 12.08% 
F-Q42    12.14% 
PC-12 cells 
 (-) control   11.3%  
Cos-7 cells  
 (-) control    10.02% 
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suggests that polyglutamine aggregates are not toxic to the cells when they are in the 
cytoplasm.  
Toxicity of intranuclear aggregates 
 In contrast, when cells were treated with F-NLS-Q42 aggregates capable of 
penetrating into nuclei (as observed in confocal microscopy), 65% of the PC-12 cells and 
66% of Cos-7 cells exhibit PI fluorescence and are hence non-viable (Figure 15). We 
then wanted to test whether or not this nuclear toxic effect is restricted to polyglutamine 
aggregates. As a control peptide for the cytotoxicity experiments, we added an NLS 
sequence to Csp-B1, a peptide fragment of a bacterial protein previously shown to make 
amyloid fibrils in vitro (Gross, Wilkins et al. 1999).  This modified peptide remains 
capable of forming amyloid fibrils (Figure2) and the aggregates are as efficient as 
polyglutamine aggregates in being taken up by cells and delivered into cell nuclei (Figure 
13).  Figure 15 shows that, in spite of this efficient nuclear uptake, F-NLS-Csp-B1 
aggregates are not toxic to Cos-7 or PC-12 cells.  Thus, the toxicity of intranuclear 
aggregates in these experiments seems to require the presence of the polyglutamine 
sequence. 
Toxicity of aggregates of a polyglutamine sequence under the pathological 
threshold: Q20 
We then addressed the question of why there is a repeat length cutoff in the 
disease onset. Is this due to the difference in the toxicity of the polyglutamine 
aggregates made from different glutamine lengths, or in the tendency of different  
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Figure 15. Flow cytometry on cell viability of nuclear aggregates. PC-12 cells 
(top series) or Cos-7 cells (bottom series) were incubated with F-NLS-Q42 aggregates 
(left) and F-NLS-CspB-1 aggregates (right) for 24 hrs, then stained with propidium 
iodide and analyzed by flow cytometry.  The individual panels show the result of one 
experiment each in which 1.2 um filtered aggregates were mixed with cells and 
evaluated for both cell uptake of aggregates (FL-1) and cell death (FL-3).  Panel labels 
reflect percent cell death by PI staining.   
F-NLS-CspB-1 16.67% 
F-NLS-CspB-1     16.66% 
F-NLS-Q42 65.14% 
F-NLS-Q42    66.36% 
PC-12 cells 
Cos-7 cells  
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polyglutamine lengths to aggregate? Although Q20 peptides form aggregates very 
sluggishly at 37 °C (Chen, Berthelier et al. 2001), it is possible to produce Q20 
aggregates in vitro by exploiting the process of freeze-concentration (Chen, Berthelier et 
al. 2002). We treated both PC-12 cells and Cos-7 cells with Q20 aggregates at the same 
molar concentration (that is, as expressed by the molar concentration of monomers in 
the aggregates) with Q45 aggregates. Figure 16 shows that aggregates of F-NLS-Q20 kill 
both PC-12 and Cos-7 cells about as effectively as do aggregates of F-NLS-Q42 (Figure 
9). Figure 16 also shows that aggregates of Q20 peptides lacking an NLS exhibit poor 
cytotoxicity, in analogy to the Q42 result. These observations strongly support the view 
that the pathological length cutoff for polyglutamine disease onset is due to the 
inefficiency of the aggregation process itself for short polyglutamine peptides. Once 
aggregates are formed, they are equally toxic regardless of the repeat length of their 
constituent peptides. 
A summary of the cytotoxicity results obtained by flow cytometry 
Figure 17 summarizes the results of three to eight (depending on the aggregates 
used) independent experiments conducted using flow cytometry evaluated PI uptake as a 
marker for cell death. Statistical analysis of the data confirms that aggregates of both long 
and short polyglutamine peptides tagged with an NLS are highly cytotoxic, while cells 
treated with aggregates of identical peptides lacking the NLS exhibit essentially the same 
low amount of cell death as do untreated control cells.  Aggregates of the NLS-tagged 
CspB-1 peptide are similarly non-toxic.  
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Figure 16. Flow cytometry on cell viability of short (Q20) aggregates. PC-12 cells 
(top series) or Cos-7 cells (bottom series) were incubated with F-NLS-Q20 aggregates 
(left) and F-Q20 aggregates (right) for 24 hrs, then stained with propidium iodide and 
analyzed by flow cytometry.  The individual panels show the result of one experiment 
each in which 1.2 um filtered aggregates were mixed with cells and evaluated for both 
cell uptake of aggregates (FL-1) and cell death (FL-3).  Panel labels reflect percent cell 
death by PI staining.   
F-Q20     11.16% F-NLS-Q20   71.21% 
F-Q20     5.19% F-NLS-Q20    38.72% 
PC-12 cells 
Cos-7 cells  
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Figure 17.  A summary of propidium iodide flow cytometry data on the cytotoxicity 
of the aggregates.  PC-12 (open bars) or Cos-7 (closed bars) cells were treated with 
various aggregates indicated in the figure.  Three to eight independent experiments were 
summarized here and the asterisk indicates data in which p ≤ 0.001 compared to control.  
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Cell viability study by MTS reduction assay 
In order to confirm the results obtained in the flow cytometry study and eliminate 
the bias that might be obtained from relying on only one method, we carried out 
additional assays to evaluate the viability of cells treated with aggregates. The MTS 
reduction assay is based on measuring mitochondrial function as an indirect way to assess 
cell viability (Gschwind 1997). Consistent with the flow cytometry results, Figure 18 
shows that the viability of both Cos-7 and PC12 cells treated with NLS-polyglutamine 
aggregates is significantly reduced compared to cells treated with polyglutamine 
aggregates without an NLS or with non-polyglutamine aggregates with an NLS (F-NLS-
CspB-1) (which are essentially the same as untreated control cells). The difference in the 
degree of cytotoxicity measured for NLS-polyglutamine aggregates using flow cytometry 
(over 50% for PC-12 cells and over 60% for Cos-7 cells) versus MTS reduction (about 
30% for PC-12 cells and about 40% for Cos-7 cells) can be explained by the difference in 
the sensitivities of different assays.  Qualitatively, the data obtained from the MTS 
reduction assay confirms the cytotoxicity results observed by flow cytometry/PI 
exclusion. 
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Figure 18.  MTS reduction assay on the cell viability after aggregates 
treatments. PC-12 (open bars) or Cos-7 (closed bars) cells were treated with various 
aggregates indicated in the figure.  Note that the ordinate here is cell survival rather than 
cell death. Data shows the mean and standard error of two to four experiments, except for 
the F-NLS-CspB-1/Cos-7 experiment, which is from a single experiment. The asterisk 
indicates data in which p ≤ 0.001 compared to control. 
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Cytotoxicity study by LDH release assay 
A summary on cytotoxicity study using the LDH release assay  
The mechanism of the LDH release assay is similar to that of the PI exclusion 
assay. The LDH assay measures the release of a cytoplasmic enzyme, lactate 
dehydrogenase (LDH), into the medium when cell membrane integrity is lost. The 
advantage of this assay over PI exclusion is that it can easily follow the course of 
cytotoxicity quantitatively without disrupting the cells. The percentage of cell death in a 
cell culture is represented by LDH activity measured in the supernant relative to the total 
possible LDH, determined after complete cell lysis (Gschwind and Huber 1995). Figure 
19 summarizes 2-4 independent experiments using the LDH release assay. The results are 
consistent with the results obtained by both flow cytometry/PI exclusion and by MTS 
reduction, with significant cytotoxicity only detected in NLS-polyglutamine treated cells. 
There is no significant difference in the results for PC-12 and Cos-7 cells. Again, because 
different assays measure different aspects of cell death, the increased cytotoxicity in 
NLS-polyglutamine treated cells (about 30% for PC-12 and about 50% for Cos-7) 
measured by the LDH release assay is slightly different from the other two methods. But 
the overall conclusion remains the same.  
Dose-response study of polyglutamine aggregate cytotoxicity  
Having established that all these measures of cell death give equivalent results, 
we took advantage of the relative ease of the LDH release assay to study the cytotoxicity  
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Figure 19.  LDH releasing assay on the cytotoxicity of various aggregates. 
PC-12 (open bars) or Cos-7 (closed bars) cells were treated with various aggregates 
indicated in the figure.  Data shows the mean and standard error of two to four 
experiments. The asterisk indicates data in which p ≤ 0.001 compared to control.
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of aggregates at different doses. We used only PC-12 cells in these studies, since we 
observed essentially no difference between the two cell lines in the cytotoxicity assay as 
described above. Figure 20 shows that aggregates of both F-NLS-Q42 and F-NLS-Q20 
exhibit similar dose-response curves in the LDH-release assay, with mid-points in the 
low uM range.  At the same time, aggregates of polyglutamine peptides lacking the NLS, 
as well as the nuclear-targeted non-polylutamine control peptide F-NLS-CspB-1, are 
completely non-toxic up to 100 uM concentration or higher.  Aggregates of a Q42 peptide 
containing a nuclear export signal, F-NES-Q42 (Table I), were similarly non-toxic up to a 
100 uM concentration (not shown).  The lack of toxicity of these control peptides, even at 
very high concentrations, emphasizes the significance of the efficient cell killing 
observed for the nuclear targeted aggregates.  There are several possible explanations for 
the slightly higher potency of the F-NLS-Q42 aggregates compared to F-NLS-Q20 
aggregates shown in Figure 20.  These include the two-fold greater mass, a possibly 
higher efficiency of cellular and/or nuclear uptake, and a lower tendency to disaggregate 
(Figure 3), of Q42 compared to Q20 aggregates. 
Time-course studies of polyglutamine aggregate cytotoxicity  
 Figure 21 shows the time course of cell death, as measured by the LDH release 
assay, for cells treated with various aggregates.  In agreement with other results described 
here, nuclear-localized aggregates of both Q20 and Q42 peptides are toxic. The time course 
of cell death induced by toxic aggregates is consistent with the time course for aggregate 
internalization.  Thus, Figure 11 shows that substantial uptake of polyglutamine 
aggregates occurs at some time between four and 24 hours.  This is consistent with the  
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Figure 20.  Dose-dependent cytotoxicity of polyglutamine aggregates.  PC-12 cells 
were incubated with various concentrations of poyglutamine aggregates and cell death 
measured by the LDH-release assay.  F-NLS-Q42, closed squares (■); F-Q42, open squares 
(□); F-NLS-Q20, closed diamonds (◆); F-Q20, open diamond (◇); F-NLS-CspB-1, closed 
triangles (▲).  The data reflects the mean values of 2-4 independent repetitions, each 
conducted in triplicate; data was normalized to a value of 20% cell death for the untreated 
cells. The average EC50 for the F-NLS-Q42 aggregates is about 3-4 uM, and for F-NLS-
Q20 aggregates 12-15 uM.  
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Figure 21.  Time course of the cytotoxicity of polyglutamine aggregates and 
monomers.  PC-12 cells were incubated with polyglutamine aggregates for over 90hours 
and cell death was measured by the LDH-release assay at various time points.  F-NLS-
Q42, closed squares (■); F-Q42, open squares (□); F-NLS-Q20, closed diamonds (◆); F-
Q20, open diamond (◇); F-NLS-CspB-1, closed triangles (▲).  Two independent 
experiments were conducted, each in triplicate; data was normalized by subtracting out 
the control value at each time point, so that percent cell death means the increased cell 
death compared to control.  
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results shown in Figure 21 that show an onset of cell killing between 15 and 18 hours 
after initiation of the experiment. Polyglutamine aggregates localized in the cytoplasm 
and non-polyglutamine aggregates localized in the nucleoplasm are not toxic for up to 90 
hours, as shown in Figure 21. In the LDH assay, the cell medium was normally 
maintained in a serum free state to avoid both a high LDH background associated with 
the serum, and the variation in that background observed for serum purchased at different 
times (this will be discussed in Chapter 9). This, however, led to more extensive death in 
control cells, so that the majority of cells are dead after 3 to 4 days due to serum 
starvation. This limited the time course study to 90 hours. Except for the increased 
background of cell death caused by serum starvation in all the experiments, the increased 
cytotoxicity caused by NLS-polyglutamine aggregates is essentially the same as in the 
previous studies using the flow cytometry/PI exclusion method. 
A live cell system monitoring a single cell for aggregate toxicity 
We attempted to visualize the dynamic structural changes occurring in cells 
treated with toxic aggregates. A live cell system was set up on the confocal microscope 
station to monitor and record cells in the process of taking up aggregates and undergoing 
cell death. In Figure 22, serial pictures from this system are shown for control cells 
maintained in the condition of high antibiotics, with mineral oil covering and a bottom 
heating plate for a course of 24 hours. As shown in Figure 22, cells can be maintained 
viable under these conditions, making possible subsequent experiments. We then used the 
system to monitor cells treated with F-NLS-Q20 aggregates. Figure 23 shows pictures of 
selected time points of a single cell during the 24 hour time course. The data, suggests  
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Figure 22. A live cell microscopic system monitoring control cell morphology over a 
24 hrs period.  PC-12 cells were maintained in the live cell system for 24 hours and 
confocal images were acquired at various time points as indicated in the figure. 
00 hrs. 2.5 hrs. 5 hrs. 7.5 hrs. 10 hrs. 
(-) control 
11.67 hrs. 15.83 hrs. 17.5 hrs. 20 hrs. 21.5  hrs. 
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Figure 23. A live cell microscopic system monitoring a single cell treated with 
F-NLS-Q20 aggregates for 24hrs. PC-12 cells (NGF-differentiated) were incubated 
with F-NLS-Q20 aggregates for 24 hours and confocal images were acquired at various 
time points as indicated in the figure. 
F-NLS-Q20 Aggregate treated 
00 hrs. 2.67  hrs. 5.67  hrs. 9.17  hrs. 12.83 hrs. 
15.83 hrs. 17.5  hrs. 17.67 hrs. 20 hrs. 21.67 hrs. 
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that the cell died at 17-20 hours, consistent with the LDH release assay time course study 
shown in Figure 22. Other cells in the field showed similar effects and a similar time 
course. The morphology of the cell death shown in the last 3 frames revealed cell 
blebbing and fragmentation, rather than swelling and leakage, suggesting that the cell 
death mechanism may be more related to an apoptotic pattern than a necrotic pattern. 
This will be further investigated in Chapter 6. 
Discussion 
Polyglutamine aggregates can be toxic to cells. 
 Debate continues as to whether it is the aggregated state of expanded 
polyglutamine sequences that is toxic to cells. The data presented by different groups are 
controversial. (See Chapter 1) The results described here clearly show that nuclear 
polyglutamine aggregates made in vitro are very toxic to mammalian cells, both PC-12 
and Cos-7. The approach taken in our experimental system, of directly introducing 
polyglutamine aggregates into cells, is relatively clean and straight-forward. It eliminates 
some factors that made earlier experiments difficult to interpret, in allowing us to uncover 
a real toxic role of polyglutamine aggregates. First, it eliminates the possibility that 
monomer or aggregation intermediates, such as those that exist at least transiently in the 
transfected cell model systems, might be the toxic species. Second, technical factors may 
limit the ability to detect the formation of small aggregates in many cell studies. This was 
confirmed, in fact, by recent studies in our lab, in which an improved detection method 
allowed detection of a new type of recruitment-competent aggregate in transfected cells 
105 
and in HD brain tissues that cannot be detected by conventional methods (A. Osmand, V. 
Berthlier, E. Johnson and R. Wetzel, unpublished). In the work described here, we 
challenge the cells with exogenous aggregates so that any toxic effects can be clearly 
attributed to aggregates. Clearly, polyglutamine aggregates can be toxic.  
The cytotoxicity of polyglutamine aggregates is linked to their nuclear 
localization 
In our model system, aggregates of polyglutamine peptides localized to the 
nucleus of the cell are highly toxic, which is consistent with the results from transfected 
cell and transgenic animal experiments, in which expanded polyglutamine containing 
proteins targeted to the nucleus (also by NLS) produce nuclear aggregates and are 
highly toxic (Klement, Skinner et al. 1998; Saudou, Finkbeiner et al. 1998; Peters, 
Nucifora et al. 1999). This requirement for nuclear localization has been implicated by a 
number of studies, as described in Chapter 1, including gene transcriptional disruption.  
In addition, the results described here suggest that polyglutamine aggregates play a 
direct role in nuclear toxicity, which is not as clear in the expressed protein systems, 
since there are both monomers and intermediates present in addition to aggregates.  
Our results show that aggregates localized to the cytoplasm, including perinuclear 
inclusions, exhibit little or no cytotoxicity. However, the more common observation of 
cytoplasmic aggregates in expanded CAG repeat disease human tissue (Gutekunst, 
Norflus et al. 2002), suggests a possible role for cytoplasmic aggregates in long-term 
toxicity, linked to neuronal dysfunction (see Chapter 1) rather than cell death. Further 
studies using our model system might be conducted to examine more subtle effects of 
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cytoplasmic polyglutamine aggregates on cell dysfunction.  An alternative explanation 
for the presence of cytoplasmic aggregates in disease tissues is that cytoplasmic 
aggregates are, in fact, benign, but that - by mechanisms as yet unknown - cytoplasmic 
aggregates occasionally migrate into the nucleus, with cataclysmic results. In any event, 
in the context of our model system, the results clearly indicate that the toxic effects of 
polyglutamine aggregates follow upon their movement from the cytoplasm to the 
nucleoplasm.  
The data supports a recruitment mechanism of cytotoxicity 
 As for the question of why nuclear aggregates are toxic, the results described up 
to this point do not provide conclusive evidence for any mechanism. However, together 
with the results of in vitro studies on the aggregation kinetics of these polyglutamine 
peptides and features of the aggregates they generate (Chen, Berthelier et al. 2001), this 
cytotoxicity study is consistent with a recruitment mechanism of polyglutamine aggregate 
toxicity. According to this mechanism, polyglutamine aggregates specifically recruit, 
sequester, and alter the activities of polyglutamine-containing proteins through a 
continuation of the aggregation process (explained in detail in chapter 1). Our results are 
consistent because (a) toxicity is only evident in the nucleus, where a lot of gene 
transcriptional factors and nuclear proteins have been identified that contain 
polyglutamine or glutamine-rich sequences; (b) aggregates of the control peptide, F-NLS-
CspB-1, are efficiently introduced into the nuclei of the cells, but produce no toxicity. 
This is consistent with the recruitment mechanism, since these non-polyglutamine 
aggregates are expected to be inefficient in recruiting polyglutamine peptides, but would 
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be expected to be equally toxic to polyglutamine aggregates according to other 
mechanisms proposed for aggregate induced toxicity (reviewed in chapter1). From this 
point of view, it is possible that the very large, easily visible super-aggregates known as 
inclusions (NIIs) may be protective to cells, to the extent that they consolidate, and 
thereby reduce the effective surface area (Chen, Berthelier et al. 2001) of smaller, toxic 
aggregates. 
Even though the present study was not designed to directly address other 
hypotheses and models of polyglutamine diseases, these experiments suggest that it is 
unlikely that the toxicity of polyglutamine aggregates is due to the saturation or 
inactivation of chaperones, proteasomes, or other cellular machinery by accumulated 
aggregates, which is an alternative hypothesis (Bates 2002). If that were the disease 
mechanism, it might be expected that nuclear Csp-B1 aggregates would be as toxic as 
polyglutamine aggregates in our experiments. 
There is growing speculation that relatively small assembly intermediates may 
play key cytotoxic roles in a number of protein aggregation-related neurodegenerative 
diseases. Amyloid assembly intermediates of a number of proteins, including proteins not 
associated with disease, have been shown to have cytotoxic properties in cellular models. 
The identification of annular assembly intermediates in early aggregation timepoints in 
the amyloid formation of Aß, α-synuclein and other proteins has drawn increasing 
support for early speculations that amyloid-related toxicity is mediated by membrane 
insertion and depolarization.  
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The toxicity reported in this paper appears to be fundamentally different from the 
above examples, however, in a number of ways. First, the toxicity of our aggregates 
requires the presence of a polyglutamine sequence, while amyloid-like aggregates of a 
similarly treated and targeted control peptide are benign. Second, the toxicity of our 
aggregates, in parallel with toxicity in other cell models of HD, requires nuclear 
localization, whereas the target of the hypothetical membrane depolarizing assembly 
intermediates prepared from other amyloidogenic proteins is presumably the outer 
membrane. Third, the polyglutamine aggregates used here appear to be mature products 
of aggregation, rather than metastable assembly intermediates. While it is an attractive 
model that all protein aggregates kill cells by a common mechanism, the weight of 
evidence to date is that polyglutamine aggregate toxicity is mediated by a set of protein
protein interactions that are very specific to the expanded CAG-repeat diseases. Studies 
described in this chapter provide further support of a recruitment mechanism of toxicity.  
Polyglutamine length cutoff in the disease mechanism is associated with 
efficiency of aggregate formation 
 We show here that nuclear-localized aggregates of polyglutamine peptides are toxic 
regardless of peptide length.  This observation supports the hypothesis that the repeat 
length dependence of disease risk in expanded CAG repeat diseases is related to the 
length dependence of aggregation efficiency.  Once aggregates are formed, as governed 
by the biophysics of polyglutamine aggregation, and once these aggregates appear in the 
nucleus, any polyglutamine peptide aggregate is toxic. The simplest explanation for the 
link between polyglutamine repeat length and disease risk and age-of-onset is that 
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expanded polyglutamine sequences kill cells by virtue of their ability to efficiently form 
toxic aggregates. 
No cell specificity observed in the system 
 Expanded polyglutamine proteins such as huntingtin are expressed in many cells 
throughout the body, and polyglutamine inclusions are observed in many brain regions in 
patient material and animal models (Reddy, Charles et al. 1999). In spite of this, only a 
small subset of neurons in highly localized regions are affected by these diseases.  This 
data seems inconsistent with our data showing that Cos-7 and PC-12 cells have equal 
sensitivity to intranuclear polyglutamine aggregates. In addition, experiments using either 
NGF differentiated PC-12 cells or undifferentiated PC-12 cells show roughly the same 
effect. Figure 24A shows a phase-contrast microscopy image of the PC-12 cells 
with/without NGF induced differentiation and Figure 24B is a cytotoxicity study on the 
different aggregates using these differentiated cells. As can be seen from the Figure 24A, 
the morphologies between the differentiated and undifferentiated PC-12 cells differ 
dramatically; however, the toxicity induced by the aggregates (Figure 24B) remains the 
same. In fact, Cos-7 cells are also susceptible to toxic effects in cellular models involving  
by over-expressing of expanded CAG repeat genes (Abdullah, Trifiro et al. 1998; Merry, 
Kobayashi et al. 1998). This is probably the experimental limitation in all the cell models, 
in which the doses of expressed polyglutamine proteins (or the preformed aggregates, in 
our case) far exceed the intrinsic expression level of the proteins in vivo. At the 
experimental conditions of our experiment, we did not observe any specificity of 
cytotoxicity in different cells. 
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Figure 24. NGF differentiated PC-12 cells and the LDH assay for their cytotoxicity 
studies. 
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Experimental factors that affect the results  
 In the cytotoxicity experiments, there are conditions that affect the results with 
respect to both the cells and the aggregates.  As discussed in Chapter 3, the limitation of 
the introducing aggregates into cells makes it difficult to explain some of the variations 
we observe with subtle changes in the experimental conditions. On the other hand, this 
negative information may also help us better understand the mechanisms at work. 
For example, we observed that cells treated with nuclear targeted aggregates made 
at 37 °C (rather than frozen concentration) exhibit a limited cell death response.  EM 
studies show that the morphologies of these two types of aggregates differ substantially 
(Chen, Berthelier et al. 2002). Furthermore, the abilities of the two types of aggregates to 
further recruit monomeric polyglutamine peptides (i.e., undergo extension) are also 
different, with the 37 °C aggregates being much less active than the -20 °C aggregates 
(Chen, Berthelier et al. 2001). This may help explain their different toxic effects. 
However, it cannot be ruled out that the toxic difference is also influenced by a decreased 
efficiency of cell uptake for the 37 °C aggregates. Similar to the above observations, 
there are conditions, like a requirement for ultracentrifugation of the soluble, monomeric 
peptide before the aggregation step, and sonication time after aggregation, that also affect 
the cytotoxicity results and which may have implications for the cytotoxicity mechanisms. 
Figure 25 is a diagram illustrating different ways in which aggregates of F-NLS-Q42 
peptides were prepared, and Figure 26 shows a summary of cytotoxicity studies on these 
aggregates.  
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Figure 25.  A diagram indicates the possible variants of the aggregates generated by 
the same peptide. 
 
Dissolve the peptide by organic solvent treatment (TFA&HFIP) 
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Figure 26. Cytotoxicity studies by LDH release assay on the experimental 
variants of aggregates of the F-NLS-Q42 peptides. The numbers is corresponding to 
aggregates showed in the previous diagram. In addition, 1 is a control; 6 is the storage of 
frozen aggregates after sonication and filtration at -80 ºC; 7 is No.6 with additional 
sonication and filtration. 
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We also observed that, even though there is no specificity between PC-12 and 
Cos-7 cells, the age and history of the PC-12 cells significantly affects their response to 
treatment with nuclear-targeted aggregates. That is, old cells (after passage over 15-20 
times after receiving from stocks from UCLA) respond poorly to nuclear aggregates, 
exhibiting little or no cell death when treated with NLS-polyglutamine aggregates. Figure 
27 is a flow cytometry study using aged PC-12 cells (passage 24), which showed 
essentially no toxicity for F-NLS-Q42 aggregates that, on young (3-5 passages) PC-12 
cells, showed high toxicity (Figure 15-16). There are at least two possible reasons: (a) old 
cells may have reduced ability to take up aggregates or to deliver them into nuclei; (b) the 
transcriptional factors (hypothetically) affected by NLS-polyglutamine aggregates may 
not be present or essential for older cells to survive. It is well-known that cultured cancer 
cell lines tend to grow more and more rapidly and require less and less growth support 
(serum or specific growth factors), suggesting that aged cells in culture may simplify the 
pathways required for viability. This has been reported in other cell lines (Hamelers, van 
Schaik et al. 2002).  
There may be additional parameters that also affect the reproducibility of these 
experiments that we did not notice and explore. For this reason, it is very important to 
follow the described protocols exactly in order to obtain similar results.  
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Figure 27. Cytoxicity study on aged PC-12 cells (24 passages) by flow cytometry 
measured PI uptaking. 
(-) control: 25.49% cell death F-NLS-Q42 treated: 23.55% cell death 
116 
 CHAPTER 5 
TOXICITY OF SOLUBLE POLYGLUTAMINE PEPTIDES 
 
Cytotoxicity study on soluble polyglutamine peptides using the LDH 
release assay 
Dose-dependent cytotoxicity of soluble polyglutamine peptides 
 To make our studies more complete, we also carried out some experiments with 
soluble polyglutamine peptides. Figure 28 shows the results of a dose-response study 
initiated by applying monomeric peptides to PC-12 cells in culture.  All of the 
experimented peptides are non-toxic up to 100 uM, with the single exception of 
monomeric F-NLS-Q42.  The toxicity observed for monomeric F-NLS-Q42 is almost 
certainly due to its strong ability to rapidly aggregate under the experimental conditions.  
In fact, at the end of the incubation period, prior to LDH-release analysis, at toxic 
concentrations of the Q42 peptide, aggregates are clearly visible surrounding and covering 
the cells, and fluorescent foci are observed in the cells by confocal microscopy as shown 
in Figure 30.  The lack of toxicity observed for monomeric F-NLS-Q20, in contrast to the 
toxicity observed for the aggregated version, again emphasizes that aggregation is 
required for cytotoxicity. 
117 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28.  Dose-dependent cytotoxicity of polyglutamine monomers.  PC-12 cells 
were incubated with various concentrations of polyglutamine monomers and cell death 
measured by the LDH-release assay.  F-NLS-Q42, closed squares (■); F-Q42, open squares 
(□); F-NLS-Q20, closed diamonds (◆); F-Q20, open diamond (◇); F-NLS-CspB-1, closed 
triangles (▲).  The data reflects the mean values of 2-4 independent repetitions, each 
conducted in triplicate; data was normalized to a value of 20% cell death for the untreated 
cells. The average EC50 for monomeric F-NLS-Q42 is about 4-5 uM, while monomeric F-
NLS-Q20 was not toxic up to 100 uM. 
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Time course of the cytotoxicity by soluble polyglutamine peptides 
 The time course of cell death in this monomer study shows that the only monomeric 
polyglutamine peptide to exhibit toxicity, presumably by virtue of contemporaneous 
aggregation, is F-NLS-Q42 (Figure 29).  The greater extent of cell killing in experiments 
initiated with monomeric F-NLS-Q42 is possibly due to the ability of smaller, nascent 
aggregates to better penetrate cell and nuclear membranes.   
Monitoring a single cell for monomer toxicity 
We also did parallel live cell experiments using solublized F-NLS-Q42 peptides, in 
which we attempted to visualize the dynamic structural changes occurring in the cells 
taking up monomer, and the process of monomer aggregation. Figure 30 shows selected 
pictures of a single cell in a 24 hr time course. The data suggests that (a) aggregates 
appear both in and outside the cell; and (b) cell die in the 20-22 hr time frame when 
there is nuclear localization of aggregates. This data is consistent with the time course 
study measured by the LDH release assay shown in Figure 29.  
Discussion 
Stronger evidence for the toxicity of aggregates 
The results using the monomeric form of polyglutamine peptides speaks against 
disease mechanisms that invoke unique toxic features of special conformations of  
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Figure 29.  Time course of the cytotoxicity of polyglutamine monomers. PC-12 cells 
were incubated with polyglutamine aggregates (A) or monomers (B) for over 90hours 
and cell death was measured by the LDH-release assay at various time points.  F-NLS-
Q42, closed squares (■); F-Q42, open squares (□); F-NLS-Q20, closed diamonds (◆); F-
Q20, open diamond (◇); F-NLS-CspB-1, closed triangles (▲).  Two independent 
experiments were conducted, each in triplicate for each. Data was normalized by 
subtracting out the control at each time point; the percent cell death is based on the 
increased cell death compared to control.  
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Figure 30. A live cell microscopic system monitoring a single cell treated with 
F-NLS-Q42 monomers for 24hrs.  PC-12 cells (NGF-differentiated) were incubated 
with F-NLS-Q42 aggregates for 24 hours and confocal images were acquired at various 
time points as indicated in the figure. 
00 hrs. 7.5 hrs. 10.5 hrs. 12.5 hrs. 13.75 hrs. 
F-NLS-Q42 Monomer treated 
15.5 hrs. 16.25 hrs. 20.25 hrs. 20.50 hrs. 22.75 hrs. 
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monomeric forms of expanded polyglutamine repeat proteins. CD data suggests that both 
monomeric Q20 and Q45 contain the same structure, random coil (Chen, Ferrone et al. 
2002). However we observed that, for Q20, only the aggregated form is toxic.  It is 
interesting that the time course for cytotoxicity is very similar for both the aggregates and 
monomer experiments (for Q42). However, it is not clear from our experiments whether 
monomeric peptides enter cells first and then aggregates intracellularly, or whether 
aggregates formed outside of the cells enter cells by the normal mechanism. It is worth 
nothing that in this experiment, the aggregates grown at 37 °C, suggesting that there is 
no intrinsic difference in the toxic morphology of 37 °C aggregates compared to -20°C 
aggregates. 
Limitations 
 Using monomer to do these experiments might be viewed as a regressive step, 
taking us back into the pool of debating whether monomers or aggregates are responsible 
for cytotoxicity. With the availability of good transfected cell model systems, the 
advantage of using monomer seems weak. It is also very hard to monitor monomer inside 
the cell, since the fluorescence from the monomeric forms of the peptides is very faint 
under the confocal microscope and only is visible after they form aggregates. One 
advantage of using exogenous peptides over transfected cells is that new sequences can 
be tried without need to construct a new vector. Our experiments with monomer were 
conducted mostly as a control for the aggregate experiments. Nevertheless, there may be 
situations in which a model involving the treatment of cells with monomer might be 
advantageous. 
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CHAPTER 6 
MECHANISMS OF POLYGLUTAMINE AGGREGATE-
ASSOCIATED CELL DEATH 
 
A requirement for new protein synthesis 
 As reviewed in Chapter 1, cell death can be divided into two major groups, 
programmed (mainly apoptosis) and non-programmed necrotic cell death. Thus, the first 
step in understanding the mechanism of cell death observed in nuclear polyglutamine 
aggregate treated cells is to assign one of these broad classifications. We used protein 
synthesis inhibitors to find out whether or not the cell death in our system requires new 
gene transcription and translation for cell death to occur.  Actinomycin D (Act. D) is an 
anti-neoplastic antibiotic. It inhibits RNA polymerase activity by blocking its binding site 
to DNA and therefore inhibits gene transcription and stops new protein synthesis. 
Cycloheximide (CHX) is an antibiotic produced by S. griseus. Its main biological activity 
is inhibition of protein translation in eukaryotes resulting in inhibition of protein 
synthesis. It has been shown that both Act.D and CHX can act as inhibitors for 
programmed cell death (Sperandio, de Belle et al. 2000). In Figure 31, we treated PC-12 
cells with 1.0 ug/ml Actinomycin D or cycloheximide 4 hours after incubation with 
nuclear aggregates. The results in Figure 31 show that increased cell death induced by 
nuclear aggregates is diminished by addition of both types of protein synthesis inhibitor. 
This data indicates that protein synthesis is required for the cell death induced by nuclear 
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Figure 31. Protein synthesis inhibitor studies.  PC-12 cells were treated with/without 
nuclear aggregates (F-NLS-Q42 or FNLSQ20) for 4 hours before adding actinomycin D or 
cycloheximide at 1.0 ug/ml, after which cells were incubated an additional 16 hours. The 
LDH assay was used to evaluate the degree of cell death. The data is presented by 
comparing cell death to the control in each group (cell death compared to control = % of 
cell death induced by aggregated / % of cell death in the control without aggregate 
treatment). 
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 aggregates. The normal interpretation of such data is that these new proteins must be 
ones required for the suicide cell death cascade; in contrast, simple necrosis should not 
require new protein synthesis. Thus, this test suggests that the cell death in our system is 
a programmed cell death, probably apoptosis. 
A requirement for caspase activation for cell death  
PARP cleavage implicates caspase activation 
 Other tests for apoptotic mechanisms inquired whether caspase activation is 
required for cell death (Chapter 1). We first used a western blot approach to detect a 
common substrate of caspase, Poly (ADP-ribose) polymerase (PARP). Specific cleavage 
of PARP from 116 kD to 85 kD fragment is frequently used to test for caspase activation 
(Lazebnik, Kaufmann et al. 1994). Thus, PARP (Figure 32) is cleaved to an 85 kD 
fragment when cells are incubated with stauroporine, which has been shown to induce 
apoptosis in a number of studies (Li, Cheng et al. 1999). Figure 32 also shows that cells 
treated with NLS polyglutamine aggregates, but not with other aggregates, exhibit 
significant PARP cleavage. This data suggests that caspases are activated during the cell 
death process, implicating an apoptotic mechanism.  
Caspase inhibitor study also implicates caspase activation 
We also carried out a second, indirect assay for the role of caspase activation by 
using a universal caspase activation inhibitor Z-VAD-FMK to see whether or not we can 
rescue the cell death induced by aggregates. Figure 33 shows an experiment, in which we
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Figure 32. Western blot for PARP cleavage.  PC-12 cells were incubated with/without 
different aggregates as indicated in the figure for 36 hours. In the positive control for 
apoptosis, cells are treated with staurosporine at 50 uM for 24 hours. The anti-actin band 
shows that equivalent amount of cellular extract were loaded in each lane of the gel. 
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Figure 33. Caspase inhibitor (Z-VAD-FMK) study. PC-12 cells were co-incubated 
with F-NLS-Q42 aggregates (filled bars) or PBS (open bars) and with Z-VAD-FMK at 
different concentrations, as indicated, for 20 hours. The LDH assay was use to evaluate 
cell death. 
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co-incubated the cells with both the F-NLS-Q42 aggregates and Z-VAD-FMK for 20 
hours. The result is that the cell death induced by the nuclear aggregates is dramatically 
decreased in the presence of caspase inhibitor compared to control without inhibitors.  
Figure 33 also shows that the cell rescue by the caspase inhibitor exhibits a dose-
dependent effect. This data clearly shows that caspase activation is required for the cell 
death, although the identity of the caspases involved is not revealed. The PARP cleavage 
and caspase inhibitor results are in agreement with the protein synthesis inhibitor results 
in implicating an apoptotic mechanism for polyglutamine aggregate induced cell death.  
DNA fragmentation and Annexin-V conjugation assay 
To further confirm the possible apoptotic cell death mechanism, we attempted to 
characterize aggregated killed cells by the biochemical hallmark of apoptosis, 
internucleosome DNA fragmentation. This was carried out in two approaches, agarose 
gel electrophoresis of DNA laddering (a serial fragmented DNA with 180-200 bp 
increments) and a sensitive ELISA assay detecting the fragmented nucleosomes.  
DNA laddering is a classic apoptosis measurement, often used to distinguish 
apoptosis from necrosis (which gives a smear of DNA with no ladder pattern). Figure 34 
shows the results of a laddering experiment, including a control DNA ladder provided by 
the manufacture. Unfortunately, none of the experimental lanes show any DNA 
fragmentation, either ladder or smear (Figure 34). We also used a more sensitive ELISA 
assay purchased from Roche Applied Science, which quantitatively measures the 
fragmented DNA by a photometric enzyme-immunoassay approach (illustrated in Figure 
35).   The experiment worked perfectly in a positive control sample (stauroporine treated  
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Figure 34. An agarose gel monitoring DNA fragmentation in cells treated with 
aggregates for 48 hours. (1) PC-12 cells (-) control; (2) F-NLS-Q42 aggregate treated 
PC-12 cells; (3) F-Q42 aggregate treated PC-12 cells; (4) Cos-7 cells (-) control; (5) F-
NLS-Q42 aggregate treated Cos-7 cells; (6) F-Q42 aggregate treated Cos-7 cells. 
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Figure 35. A diagram illustrating the principle of detecting fragmented DNA 
using ELISA assay (from Roche Applied Science). POD is a peroxidase conjugate that 
react with ABTS substrate and produce a color that can be measured at OD 405 nm.
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PC-12 cells), but none of the aggregate treated PC-12 cells showed DNA fragmentation 
using this method (Figure 36). As we clearly see cell death induced by nuclear 
polyglutamine aggregates by the other cell viability studies, it is hard to interpret these 
negative DNA fragmentation results with any known cell death models. One possible 
explanation for these negative results is that fragmented DNA (negatively charged) might 
bind to the aggregates (positively charged) and cause precipitation during the 
centrifugation step to for extracting DNA. In confirmation of this, Figure 36 (last lane) 
shows diminished DNA fragments after simply incubating the already fragmented DNA 
(after stauroporine treatment) with polyglutamine aggregates. Thus, DNA laddering 
might be occurring in polyglutamine aggregate-treated cells, but not be observable. In the 
future, in order to visualize DNA fragmentation, it maybe possible to modify the DNA 
extraction conditions or use other assays that do not involve centrifugation, such as an in 
situ TUNEL assay to avoid the precipitation of the fragmented DNA.  
We also tried another assay widely used in apoptosis studies, the Annexin V 
binding assay. When cells undergo apoptosis, the membrane phosphatydylserine (PS), 
which is normally located on the cytoplasmic side of the cell membrane, is translocated 
and exposed on the cell surface. This can be detected using a human vascular 
anticoagulant, annexin V, which selectively binds to PS (van Engeland, Nieland et al. 
1998). We used Annexin-V labeled with a fluorescent tag (purchased from Molecular 
Probes, Inc.), which can be assayed by microscopy or flow cytometry.  Figure 37 shows a 
confocal microscopic image of F-NLS-Q42 aggregate-treated cells stained with tagged 
annexin V, indicating possible annexin staining. However, annexin V can also stain  
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Figure 36. ELISA assay detecting DNA fragmentation. PC-12 cells were incubated 
with different aggregates for 22 hours. The cells were collected by centrifugation and 
lysed using mild detergent. The fragmented DNA was collected to perform the ELISA 
assay for detecting the fragmented DNA. (-) control is the cells with no aggregate 
treatment; Stauroporine (STS) treated cells are a positive controlfor apoptosis; Another 
positive control was a sample of fragmented DNA provided by the manufacture; the last 
lane is the supernant collected form incubation of F-NLS-Q42 aggregates with cells 
treated with STS for 48 hours, to test whether the aggregates could compromise the 
detection of DNA fragments. 
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Figure 37. A confocal microscopic image of Annexin V binding of the PC-12 cells 
treated with F-NLS-Q42 aggregates.   Aggregates are green and Alexa Fluor 647 
conjugated annexin V is red in the figure. 
F-NLS-Q42  aggregates treated cells 
133 
necrotic cells, since after membrane integrity is lost annexin V can pass through the 
membrane and bind to PS resident on the inner surface. Thus, annexin labeling can only 
be rigorously interpreted using a third indicator, for membrane integrity (which is still 
intact in early apoptosis, but lost in necrosis or late apoptosis). PI staining for the nucleus 
upon loss of cell membrane integrity is normally interpreted as evidence for necrosis.  It 
should be possible to detect early apoptosis (while the membrane is still intact) in the 
cells treated with the NLS-polyglutamine aggregates. This requires 3 different 
fluorescence channels (green for polyglutamine aggregates, red for PI, another color for 
Annexin V), which we is beyond the capabilities of our flow cytometry facility.   
A summary of these cell death mechanism results, compared to the expected 
results for apoptosis and necrosis cell death mechanisms, is listed in Table 9.  
 
Discussion 
Mechanism of cell death induced by NLS-polyglutamine aggregates  
 Given the fact that the cell death in our model system requires protein synthesis 
and caspase activation, the mechanism of the cytotoxicity of nuclear polyglutamine 
aggregates in our system seems to be clearly an apoptosis-type mechanism. According to 
the recruitment hypothesis, nuclear aggregates recruit and sequester polyglutamine-
containing proteins such as transcriptional factors, which then cause abnormal gene 
transcription or other effects. It is well-known that transcription dysregulation can 
become so severe that cells can be induced to undergo apoptosis (Cha 2000). Such an  
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Table 9. Comparison of the cell death induced by the nuclear polyglutamine 
aggregates with response typical of apoptosis and necrosis 
 Apoptosisa Necrosisa Aggregate-treated cell deathb 
Annexin V binding + + + 
Internucleosomal DNA 
fragmentation: 
   
DNA laddering gelc + - - 
DNA fragmentation ELISAc + - - 
Caspase activity:    
PARP cleavage (118 kD to 85 kD) + - + 
Inhibition by:    
z-VAD (caspase inhibitor) + - + 
Protein synthesis inhibitor:    
Actinomycin D sometimes - + 
Cycloheximide sometimes - + 
a from the literature 
b in all cases, cells were treated with aggregates of F-NLS-Q42 
c experimental result compromised by direct aggregate-DNA interaction as described in 
text.
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apoptotic mechanism, in the absence of phagocytes, will eventually cause the cell die 
completely, with development of some necrotic features such as membrane disruption. 
This presumably explains the ability of the LDH release and PI exclusion assays to 
monitor cell death in our model, in spite of its initiation by an apoptotic pathway 
(illustrated in Figure 38). 
Further studies need to be carried out 
 So far, we have not directly approached the question of gene transcriptional 
dysregulation. A DNA microarray or differential display RT-PCR can be carried out in 
the future to study the changes in the profile of gene transcription in nuclear aggregate 
treated cells. This will be very valuable not only to understand this model system better, 
but also to compare data on our system with data already generated from the transfected 
model system.  
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Figure 38. A diagram of the hypothesis on the events of cytotoxicity induced by 
nuclear polyglutamine aggregates.  
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CHAPTER 7 
 EFFECT OF A POLYGLUTAMINE ELONGATION 
INHIBITOR ON AGGREGATE-INDUCED CELL DEATH 
 
An elongation inhibitor protects cells from aggregate – associated cell 
death 
 In a recent paper, Thakur and Wetzel (Thakur and Wetzel 2002) explored the 
structural organization of polyglutamine aggregates. By introducing Pro-Gly pairs (which 
has to be positioned at the turn position in a β-sheet) in the polyglutamine sequence, 
Thakur and Wetzel discovered a peptide named PGQ9, that aggregate in an identical 
fashion to a simple polyglutamine peptide of the same length, suggesting that PGQ9 
probably adopts the same β-sheet structure as the polyglutamine sequence. To confirm 
this, they introduced additional prolines in positions thought to be essential for extended 
chain formation in the proposed β sheet structure. In fact, such peptides, one of which is 
PGQ9(P2,3), do not aggregate, confirming the structural hypothesis.  
The complete amino acid sequence of PGQ9(P2,3) is listed in Figure 39. 
Subsequent studies on in vitro fibril elongation of normal polyglutamine aggregates done 
in the presence of this peptide revealed that, PGQ9(P2,3) can also inhibit this elongation. 
To test the hypothesis that the recruitment activity of an aggregate is important for its 
toxicity, we asked whether or not this recruitment inhibitor can prevent cell death in our 
model system. We used different amounts of the peptide from 0 uM up to 100 uM. The 
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Figure 39. Study of the protection effect of an elongation inhibitor on the 
cytotoxicity of F-NLS-Q42.  PC-12 cells were pre-incubated with different doses of 
PGQ9(P2,3), as indicated in the figure, for 24 hours, then F-NLS-Q42 aggregates were 
used to treat the cells according to the usual method. A is the original data showing cell 
death measured by LDH release; B is this data corrected by subtracting out the PBS 
control; C is the data shown in B normalized by the equation:  % of protection from F-
NLS-Q42 aggregates = (increased cell death caused by the aggregates without the 
inhibitor  increased cell death caused by the aggregates with the inhibitor at each dose 
point) / increased cell death caused by the aggregates without the inhibitor.  
139 
0%
20%
40%
60%
80%
100%
0 10 20 30 40 50 60 70 80 90
concentration of the inhibitor (uM)
%
 o
f c
el
l d
ea
th
 (L
D
H
 a
ss
ay
)
agg PBS
 
0%
10%
20%
30%
40%
50%
0 10 20 30 40 50 60 70 80 90
concentration of the inhibitor (uM)
in
cr
ea
se
d 
ce
ll 
de
at
h 
co
m
pa
re
d
to
 c
on
tr
ol
 
0%
20%
40%
60%
80%
100%
0 10 20 30 40 50 60 70 80 90
concentration of the inhibitor
%
 o
f p
ro
te
ct
io
n 
fr
om
 N
FQ
42
ag
gr
eg
at
es
PGQ9(P2,3):  K2-Q9-PG-Q4PQ4-PG-Q4PQ4-PG-Q9-K2          46  amino acid
A 
B 
C 
140 
 inhibitor peptide was preincubated with the cells for 24 hours, after which aggregates 
were incubated with the cells with the continued presence of the inhibitor. Figure 39A 
shows that the cell death induced by F-NLS-Q42 aggregates was significantly inhibited 
by the presence of the elongation inhibitor. By further processing the data by correcting 
for the direct cell toxicity of the inhibitor in the PBS control, Figure 39B shows that the 
cell death contributed solely by nuclear polyglutamine aggregates is decreased from 25% 
to 5%, as inhibitor concentration increases.  Figure 39C presents the percentage of the 
cell death rescued by the inhibitor. The data reveal a significant, dose-dependent cell 
death rescue effect by the inhibitor. At 80 uM concentration of the inhibitor, up to 80% of 
the cell death induced by the nuclear aggregates was blocked.  This rescuing effect is 
most probably due to the inhibition of the recruitment of other polyglutamine peptides, 
which greatly supports the recruitment mechanisms of toxicity of polyglutamine peptides. 
Discussion 
 This data is the most compelling data available indicating that the polyglutamine-
recruitment activity of aggregates is responsible for polyglutamine aggregate toxicity. It 
also suggests a possible drug discovery approach focusing on elongation inhibition.   
 It is still unclear as to how PGQ9(P2,3) works, since we havent visually traced the 
peptide after incubating it with the cells. For example, the peptide may remain in the 
medium, where it binds to the aggregates and is subsequently delivered into the nucleus 
together with NLS-aggregates. Once there, it could prevent further recruitment of other 
polyglutamine containing transcriptional factors and rescue the cell. Alternatively, the 
peptide may be transported into the cells first. For a potential treatment using this peptide, 
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we need eventually to deliver the peptide into cells or even the nucleus. A this time, we 
cannot demonstrate whether or not the peptide was delivered into nucleus by incubating it 
with the cells.  Further studies on the inhibitor peptide thus need to be carried out. 
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CHAPTER 8  
CONCLUSIONS 
 
In conclusion, we have developed a new cell model system to study the mechanisms 
of polyglutamine aggregate toxicity. 
The results described in this dissertation suggest that polyglutamine aggregates made 
in vitro can be efficiently delivered into mammalian cells, both PC-12 cells and Cos-7 
cells. Facilitated by NLS sequences, aggregates can be delivered to the nuclei of the cells. 
The rapid cytotoxicity of polyglutamine sequences requires both their aggregation and 
their nuclear localization.   
In our model system, aggregates of polyglutamine peptides localized to the 
cytoplasm, including perinuclear inclusions, are not toxic.  Likewise, aggregates of non-
polyglutamine sequences delivered to the nucleus are not toxic. Nuclear-localized 
aggregates of polyglutamine peptides are toxic regardless of peptide length. F-NLS-Q20 
aggregates made in vitro and introduced into the nucleus of the cell are as toxic as Q42 
aggregates.  This supports the hypothesis that the repeat length dependence of disease 
risk in expanded CAG repeat diseases is related to the length dependence of aggregation 
efficiency.  Once aggregates are formed, as governed by the biophysics of polyglutamine 
aggregation, and once these aggregates are delivered to the nucleus, any polyglutamine 
peptide aggregate is toxic.  Monomeric polyglutamine sequences are toxic only to the 
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extent that they can aggregate during the course of the experiment and are targeted to the 
nucleus.  
Cell death induced by the nuclear polyglutamine aggregates is a programmed cell 
death requiring caspase activation, which strongly suggested an apoptotic cell death 
pattern. The peptide, PGQ9(P2,3), which inhibits the recruitment of other polyglutamine 
sequences by polyglutamine aggregates, effectively reduces the cell death caused by 
nuclear aggregates. This further supports a recruitment mechanism for the cytotoxicity 
observed in our model system.  
The new cell model system can be useful in testing new in vitro inhibitors at the 
cellular level during the drug discovery process.  The ability to deliver such aggregates 
into different cell types should make possible a variety of studies on the biochemical 
details of cytotoxicity pathways. 
Further studies to characterize the gene transcriptional profile changes in the system 
by DNA microarrays or differential RT-PCR are needed to confirm the proposed 
polyglutamine recruitment/apoptosis mechanism. The study described here was designed 
to evaluate the fundamental toxic properties of the polyglutamine sequence itself.  The 
surrounding polypeptide sequences of actual disease-associated expanded polyglutamine 
proteins and their cellular expression profiles may modulate disease features through a 
number of mechanisms.  It may be possible to conduct further experiments on aggregates 
of the disease proteins themselves to evaluate some of these effects. It will also be very 
valuable to conduct the same experiment in primary striatal neurons or cultured neuronal 
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tissues and analyze more subtle effects of the aggregates on neuronal function under non-
toxic conditions.  
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CHAPTER 9 
MATERIAL AND METHODS 
 
Peptides and growing in vitro aggregates 
Peptides   
 The peptides used in these experiments were prepared by solid-phase synthesis at 
the Keck Biotechnology Center of Yale University.  The polyglutamine peptides 
contained flanking pairs of lysine residues to gain a net positive charge on the peptide at 
PH 7 to improve solubility and thus allow control over the aggregation reaction (Chen, 
Berthelier et al. 2001).  A control peptide derived from the bacterial cold shock protein B 
(CspB-1) was also obtained (Gross, Wilkins et al. 1999).  All peptides were synthesized 
with a fluorescein group on the N-terminus to facilitate microscopy and flow cytometry 
detection.  Some peptides also included a nuclear localization signal peptide sequence 
(NLS) (Kalderon and Smith 1984) or nuclear export sequence (NES) (Mowen and David 
2000). A pair of Gly residues was designed into the interface between the NLS (or NES) 
and the polyglutamine stretch to insure accessibility of the NLS (or NES) in the context 
of the aggregate.  Peptides were used without purification, and HPLC analysis showed 
that the peptides contained some glutamine deletion impurities (Berthelier, Hamilton et al. 
2001) as well as some peptides lacking the N-terminal fluorescein. These impurities do 
not appear to have influenced the results. In the cytotoxicity inhibitory study described 
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later, a polyglutamine peptide elongation inhibitor, discovered by mutational analysis in 
our laboratory, and named PGQ9(P2, 3) (Thakur and Wetzel 2002), was used  to test the 
effect of elongation inhibition on cytotoxicity. All the peptides used in the study are listed 
in Table 8. 
Growing in vitro aggregates   
 Peptides were processed by first dissolving and rigorously disaggregating the 
lyophilized solid-phase synthesis product using an organic solvent treatment followed by 
ultracentrifugation of a pH 3 aqueous solution (Chen and Wetzel 2001). To grow 
aggregates, the pH 3 solution was neutralized to pH 7 using a buffered concentrated (10X 
PBS) and the peptide concentration was adjusted to 10 uM using 1X PBS as required. 
This solution was snap frozen in liquid N2 and incubated for 48 hrs at 20 °C.  This 
frozen reaction mixture was then thawed and centrifuged for 30 mins at 14,000 X g to 
collect the aggregates.  HPLC analysis of the supernatant gives the amount of 
unaggregated material and allows calculation of an approximate value for the mass of 
aggregated peptide.  It should be noted that the aggregation actually occurs when the 
frozen solution is stored at 20 °C, by the assistance of the process of freeze 
concentration (Chen, Berthelier et al. 2002).  In the earlier experiments reported here, a 
24 hrs preincubation of monomer was included before the snap-freezing step in the 
preparation of aggregates, but this was later eliminated without any effect on toxicity. 
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Sonication and filtration method to control the size of the aggregates 
 Aggregate size was modified by a two-step procedure involving sonication and 
membrane filtration.  Aggregates were washed once with PBS using centrifugation at 
14,000 X g to collect the aggregates.  Aggregates were resuspended in PBS at a 
concentration of approximately 100 ug/ml.  Sonication was accomplished with a probe 
sonicator at 0 °C in six pulses of 30 secs each.  Sonicated aggregates were manually 
filtered through a 1.2 um Acrodisc syringe filter (Gelman Sciences).  In some cases, the 
filtrate was then further filtered sequentially through a 0.8 um filter, a 0.45 um filter and a 
0.22 um filter.  Attempts to pass the aggregates through a 0.1 um filter failed due to high 
back pressure.  The efficiency of filtration was determined by comparing the fluorescence 
signal of a suspension of filtered aggregates to that of non-filtered aggregates; triplicates 
of a 100 ul aliquot were diluted 4 times into wells of a microtiter plate and fluorescence 
monitored on the Wallac Victor 2 plate reader with excitation at 485 nm and emission at 
535 nm.  Determined by this method, about 50-80% of total sonicated aggregates were 
recovered from 1.2 um filter; 40-60% from 0.45 um filter; and 30-50% from 0.22 um 
filter. The aggregate suspensions were then adjusted to 10 uM concentration (monomer 
peptide equivalent) before applying them to cells. Aggregate preparation is summarized 
schematically in Figure 25. 
Soluble peptide preparation 
Monomers used in the studies were prepared by the standard method of 
processing the peptides as described above, without further growing the aggregates. After 
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ultracentrifugation, the pH 3 solution was neutralized to pH 7 using a buffer concentrate 
(10 X PBS) and immediately used to treat cells. 
Liposome encapsulation 
 Liposome encapsulation of aggregates was accomplished using a commercially 
available pre-liposome formula (L-α-phosphatidylcholine and β-oleoyl-γ-palmitoyl 
cholesterol; Sigma L3906) according to the recommended procedure.  Briefly, a 0.2 ml 
PBS suspension of aggregates was added to the dehydrated lipid film provided by the 
manufacturer, and the resulting suspension vortexed and then supplemented with 0.8 ml 
fresh basal medium. 
Cell culture and treatment 
Cell culture 
 Cos-7 cells were purchased from the ATCC (CRL-1651) and were cultured in 
Dulbeccos modified Eagles medium (DMEM) supplemented with 10% fetal bovine 
serum, 4 mM L-glutamine, and antibiotics.  PC-12 cells, kindly provided by Dr. Erik 
Schweitzer, were maintained in DMEM high glucose medium supplemented with 5% calf 
serum (Hyclone), 5% horse serum, and antibiotics.  Medium was changed every other 
day; cells were plated at 100,000 / cm2 density onto a 6-well plate the day before 
treatment with aggregates.  For the LDH and MTS experiments, cells were plated in 
phenol red-free and serum-free medium for 24 hrs before the assay.   
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NGF differentiation of PC-12 cells 
In some of the microscopy imaging and apoptosis studies, PC-12 cells were also 
differentiated into neuron-like cells by nerve growth factor (NGF) (Li, Cheng et al. 1999). 
In these studies, cells were plated at 50,000 / cm2 density onto either 24-well plates or P-
100 plates for 24 hours with medium containing 10% serum for proper growth and 
attachment. Then, the medium was replaced with basal medium without serum containing 
50 ng/ml NGF (Sigma) for 24  48 hours to allow the PC-12 cells to properly 
differentiate into neuron-like cells before treatment with aggregates. 
Treatment of the cells with aggregates or soluble peptides 
 For incorporation of unpackaged aggregates or monomers, cells were washed in 1X 
PBS and incubated with 10 uM aggregates or monomers for 24 hrs.  For liposome 
packaged aggregates, washed cells were mixed with liposome-encapsulated aggregates 
(see above) for 4 hrs, after which the liposome mixture was removed from the plastic-
attached cells by several washes with PBS.  Fresh culture medium was then added, and 
the cells were incubated for another 20 hours. 
Isolation of cell nuclei 
 Nuclei were isolated by a modification of the protocol of Hann et al (Hann, Dixit et 
al. 1994). Cells were lysed in NP-40 lysis buffer (0.6% NP-40, 0.1% BSA and 0.15 M 
NaCl) for 10 minutes on ice.  Nuclei were collected by centrifugation at 500 X g for 5 
minutes and washed twice, then re-suspended in PBS.  Isolated nuclei were stained for 
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contrast with 50 ug/ml propidium iodide (PI) for 5 minutes before being examined by 
confocal microscopy. 
Microscopy and flow cytometry analysis   
Electron microscopy analysis 
Aggregates were adsorbed onto carbon mica grids and negatively stained with 
0.25% w/v potassium phosphotungstate solution. Images were collected on a Hitachi 500 
electron microscope (Hitachi, Tokyo) at the microscopy center in Division of Biology, 
University of Tennessee, Knoxville. 
Confocal microscopy  
 Cells were collected by first incubating with 1 ml per well of a solution of 0.5 
mg/ml trypsin in a PBS-EDTA buffer (BioWhittaker, #17-161) until detachment was 
observed under the light microscope (about 1 min).  At this point 2 ml per well of serum-
containing culture medium was added and the suspension immediately transferred to a 
centrifuge tube.  Cells were collected by centrifugation at 1,000 X g for 5 min, and then 
washed twice with PBS using the same centrifugation conditions.  The washed cell pellet 
was resuspended in 1 ml PBS.  The cell suspension was plated on a chamber slide 
(Nalgene Nunc International, Lab-Tek II Chamber slide system) and analyzed within 4-6 
hours by confocal microscopy.  Confocal microscopy was conducted using a Leica SP2 
laser scanning confocal microscope.  
151 
Live-cell microscopic system 
PC-12 cells were plated onto a special culture dish that can be heated evenly.  In 
the culture medium, 50 ng/ml NGF was used to provide a better morphology of the cells; 
doubled concentration of antibiotics were used to limit the chance of contamination.  The 
culture dish containing the cells was carefully transferred onto a special stage mounted 
onto the confocal microscope. The stage was connected to a temperature control system, 
which was set up to maintain 37 °C.  The whole system, called Delta T Open Dish Live-
microscopy System, was purchased from Bioptechs Inc. A special lens dipping into the 
culture dish was used to monitor the cells, and the images were collected automatically 
every 10-15 minutes by the computer. Once the focus was adjusted, the remaining area of 
the dish was covered with mineral oil to eliminate the evaporation of the culture medium 
and decrease the chance of contamination.  A picture of the experimental setup is in 
Figure 40.  
Flow cytometry analysis 
 Cells were injected into a FACScan (Becton-Dickinson, San Jose CA).  Excitation 
at 488 nm allowed observation of both the fluorescein-tagged aggregates (FL-1, emission 
530 nm) and the propidium iodide stained dead cells (FL-3, emission 650 nm).  At least 
10,000 events were collected for each sample and analyzed using Cell Quest software 
(Becton-Dickinson). 
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Figure 40． The configuration of the live cell microscopic system.
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Cell Viability studies 
Flow cytometry monitored PI incorporation 
To assess cell viability, a suspension of washed cells after treatment with 
aggregates was stained with 50 ug/ml PI for 5-10 minutes and then injected into a 
FACScan as described above. Cell death was measured by the percentage of cells 
containing PI-stained nuclei, which indicates that cell membrane integrity was lost when 
the cells died.  
LDH release assay 
 The lactate dehydrogenase (LDH) release assay (Decker and Lohmann-Matthes 
1988) was used to assess cell death by measuring the activity of the cytosolic enzyme 
LDH released into the cell medium.  LDH activity was quantified using a linked enzyme 
assay.  In the oxidation of lactate to pyruvate by LDH, the NAD+ cofactor is reduced to 
NADH.  NAD+ is regenerated from the NADH by the action of the enzyme diaphorase in 
the reduction of the INT tetrazolium ion to its corresponding formazan product.  The red 
formazan product is then quantified in a spectrophotometer.  The assay was conducted 
using the Promega CytoTox 96 assay kit (#G1780) with some modification of the 
manufacturers protocol.  After 24 hr incubation of the cells with polyglutamine 
aggregates, 200 ul of medium was removed and centrifuged for 5 min at 14,000 X g to 
remove aggregates and cell material.  Three aliquots of 50 ul each of the supernatant were 
pipetted into microplate wells, followed by 50 ul per well of the diaphorase plus 
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substrates solution, and the plate incubated 30 mins in the dark at RT.  The reaction was 
stopped by addition of 50 ul 1 M HOAc, and the absorbance read at 490 nm in a 
SpectraMax Plus UV-VIS microtiter plate reader (Molecular Devices, Inc.).  The 
maximum LDH release of the cells was assessed by incubating a control plate of cells 
with 100 ul/ml of a 9% v/v Triton X-100 solution for 45 mins at 37 °C.  A blank value 
was obtained by treating an aliquot of culture medium with the assay reagents; all LDH 
values were corrected by subtracting this blank value.  Relative cytotoxicity was 
calculated by dividing LDH release for a particular experiment by the total LDH content 
of cells determined after Triton X-100 lysis. It should be mentioned that, in the LDH 
release assay, serum added to the culture medium contains a high LDH background, and 
this background varies with serum purchased at different times. Presumably, there is 
LDH in animal sera with the amount of LDH varying depending on the species and the 
health or treatment of the animal prior to the collecting serum. This high and variable 
background can be eliminated by growing cells in serum free media, which, however, 
introduces the disadvantage of greater cell death due to serum starvation.  
MTS reduction assay 
 Cell death or dysfunction as indicated by diminished activity of mitochondrial 
dehydrogenases was assessed using the MTS assay, a modification of the standard MTT 
assay (Shearman 1999).  Viable cells actively regenerating NADH and NADPH, were 
incubated with the MTS tetrazolium substrate (3-(4,5-dimethylthiaxol-2-yl)-2,5-diphenyl 
tetrazolium bromide) plus the electron coupling agent phenazine ethosulfate, carry out the 
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reduction of the tetrazolium to the corresponding formazan product, which can be 
quantified by its red color in a spectrophotometer.  The procedure was carried out using 
the CellTiter 96 Aqueous One-Solution Cell Proliferation Assay kit (Promega #G3582) 
by a modification of the provided protocol.  After 24 hr incubation of cells with 
aggregates, cells were incubated with 200 ul of assay solution to 1 ml of cell culture and 
the mixture incubated in a 24-well sterile microplate for 4 hr at 37 °C, 5% CO2.  The 
mixture was transferred to a microtube and centrifuged at 14,000 X g for 5 mins.  The 
entire supernatant was then transferred to a 1 ml cuvet and the absorbance read in the 
cuvet port of the SpectraMax Plus UV-VIS microplate spectrophotometer (Molecular 
Devices).  A maximal MTS reduction value was determined for control cells not 
otherwise treated, and a reagent blank was determined by treating culture medium alone 
with MTS reagents.  Relative cell survival was determined by dividing the corrected A490 
for a particular experiment by the corrected A490 for untreated cells. 
Apoptosis studies 
Western Blot for PARP cleavage detection 
 Poly (ADP-ribose) polymerase (PARP) is a 116 kD protein involved in normal 
DNA repair function (Smulson, Simbulan-Rosenthal et al. 2000). PARP is a substrate for 
the executive caspases (caspases 3, 7) during apoptosis (Lazebnik, Kaufmann et al. 1994). 
It is cleaved into an 85 kD carboxyl terminal fragment and a 25 kD amino terminal 
fragment by activated caspases (Lazebnik, Kaufmann et al. 1994). This is a widely used 
method to detect the activation of caspases and for studying apoptosis. Anti-PARP (Santa 
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Cruz Biotechnology, Inc) recognizing the C-terminus of PARP can detect both 116 kD 
and 85 kD fragments in a western blot. After 24-48 hours of treatment by aggregates, 
both floating and attached cells were collected and lysed in PARP lysis buffer (50 mM 
Tris-HCl, pH 6.8, 8 M urea, 5% β-mercaptoethanol, 2% SDS, and protease inhibitors) by 
sonication for 30 s on ice (Xu, Shi et al. 2002). Total protein concentration in the cell 
lysate was determined by Micro BCATM protein assay reagent kit (Pierce). An equal 
amount of total protein was subjected to electrophoresis on a 4-20% Tris/glycine SDS-
PAGE gel and the gel electrotransferred to a polyvinylidene fluoride membrane 
(Invitrogen). The membranes were then probed with anti-PARP antibody, and visualized 
by ECL-Plus (Amersham Pharmacia Biotech). 
Caspase inhibitor study 
Z-VAD-FMK (Z-Val-Ala-Asp-CH2F) (Calbiochem) is a cell-permeable, general 
caspase inhibitor. It acts by binding to the active site of caspases and inhibiting its 
activity irreversibly, thereby also inhibiting apoptosis. PC-12 cells were plated in 24 well 
plates and treated with aggregates. Different amounts (0, 12.5 and 25 uM)) of Z-VAD-
FMK was added to the cell medium and incubated for 24-48 hours. The LDH assay was 
used to study the difference in cell death between aggregate treated cells with or without 
added Z-VAD-FMK. 
Protein synthesis inhibitors study 
 Actinomycin D (Act. D) is an anti-neoplastic antibiotic. It inhibits RNA 
polymerase activity by blocking its DNA binding site and therefore inhibits gene 
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transcription and stops new protein synthesis. Cycloheximide (CHX) is an antibiotic 
produced by S. griseus. Its main biological activity is inhibition of protein translation in 
eukaryotes resulting in inhibition of protein synthesis. It has been shown that both Act.D 
and CHX can act as inhibitors of programmed cell death, which requires new protein 
synthesis (Sperandio, de Belle et al. 2000). After 4 hours of treatment with aggregates 
(described as above), cells were treated with 1.0ug/ml Act.D or CHX by direct adding 
into the cell medium to see if they can inhibit the cell death observed in the LDH assay. 
DNA fragmentation study 
DNA laddering 
 After treated with aggregates, cells, both attached and floating, were collected and 
washed twice in PBS. The cells were lysed in a lysis buffer containing 10nM EDTA, 50 
mM Tris PH 8, 0.5% sodium lauryl sarcosine, 0.5mg/ml proteinase K and the total cell 
DNA was extracted by phenol-chloroform extraction, precipitated by addition of sodium 
acetate and centrifuged at 14,000rpm for 10 min at 4 °C.  The DNA pellet was then 
washed with ethanol and resuspended in TE buffer (10mM Tris PH 7.4 and 1mM EDTA). 
15 ug of DNA was loaded on a 1% agarose gel. The gel was stained with ethidium 
bromide and visualized with UV. 
DNA fragmentation ELISA assay 
 The ELISA assay was purchased from Roche Applied Science as a kit. The 
procedure is as suggested by the manufacture. Cells were plated in a 24 well plate at 5 X 
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104/ well and treated with different aggregates for 24 hours.  Then cells were collected 
and washed in PBS, then lysed in the provided lysis buffer for 30 min at room 
temperature. The cell lysate was centrifuged at 200 g for 10min to collect the supernate 
containing the fragmented DNA. 20ul of the supernate was transferred to a streptavidin-
coated plate. 80ul of the mixture containing the anti-histone-biotin and anti-DNA-POD 
(peroxidase conjugated) were added to the sample in the microtiter plate. The plate was 
covered and incubated on a shaker for 2 hours at room temperature. After incubation, the 
solution was removed and the plate was washed thoroughly with the incubation buffer. 
Then ABTS (2, 2- Azinobis[3-ethylbenothiazoline-6-sulfonic acid]-diammonium salt), 
which is a substrate for peroxides, was added, which yields a green end product 
measuarable at 405 nm in a SpectraMax Plus UV-VIS microtiter plate reader (Molecular 
Devices, Inc.)  
Annexin V binding study 
 Cells were treated with aggregates for 16 hours and then collected and washed 
twice in PBS. Then the cells was resuspended in Annexin-Binding buffer (10mM HEPES, 
140 mM NaCl and 2.5mM CaCl2, PH 7.4). 10 ul Annexin V Alexa Fluor 647 conjugate 
(Molecular Probes) was then added to the 100 ul of cell suspension and incubated for 15 
minutes at room temperature. Cells were then washed with Annexin-Binding buffer twice 
and dipped onto a slide to be observed under confocal microscope. 
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Inhibitor studies 
 The polyglutamine aggregation elongation inhibitor PGQ9(P2,3) (listed in Table 3) 
was pre-incubated with cells at the concentration range from 0 to 100 uM for 24 hours 
before treatment with aggregates or monomers. Cell death was evaluated by LDH assay 
after 24-48 hours incubation with aggregates. 
Statistics 
 Three to eight independent studies (depending on the aggregate tested), including 
aggregate preparation and cell treatment, were conducted for flow cytometric analysis of 
cell viability.  Two to four independent experiments were conducted for LDH and MTS 
assays.  Bar graph data are expressed as the mean +/- the standard error.  Statistical 
significance was analyzed by one-way ANOVA using the software package SPSS 10.0 
(SPSS, Chicago IL).  A p value ≤ 0.001 is considered significant. 
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